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ABSTRACT

MECHANISMS OF CELL DEATH INITITATED IN HERPES SIMPLEX VIRUS
THYMIDINE KINASE EXPRESSING COLON TUMOR CELLS TREATED WITH
GANCICLOVIR AND UCN-01
Christina Elizabeth Ahn
Eastern Virginia Medical School and Old Dominion University, 2005
Director: Dr. Richard R. Drake

Metastatic colon carcinoma is the second leading cause of death from
malignancy in the United States, and development of more effective treatments is
essential. Heterologous expression of Herpes Simplex Virus Thymidine Kinase
(HSVtk) in combination with the prodrug, ganciclovir (GCV), has shown great
promise for the genetic therapy of many cancers, but most patients have had
only a partial or minimal response to the therapy. After screening a panel of two
drug combinations, our laboratory has shown that the combination of GCV and
the protein kinase inhibitor UCN-01 (7-hydroxystaurosporine) enhances tumor
cell death more effectively than either drug alone. However the molecular basis
of this enhancement was unknown, and it was investigated by studying the
effects on the cell cycle, DNA metabolism and damage signaling, and finally
tested in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Colon tumor cells treated with GCV arrest in S-phase, and cells treated with the
combination of UCN-01 and GCV also undergo S-phase specific cell death.
However, UCN-01 treatments induced the disappearance of key mitotic proteins
and had variable effects on the cell cycle.
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Distinct immunofluorescence patterns, phosphorylation of histone H2AX,
and elution out of agarose plugs after pulsed field gel electrophoresis were
detected after UCN-01 treatment, and it was concluded that UCN-01 can cause
DNA double strand breaks in treated cells. It was shown that this damage most
likely resulted from UCN-01 interacting or damaging the DNA itself and was not
simply due to inhibition of endogenous damage repair mechanisms.
Several HSV-TK active site variants were also studied for S-phase specific
apoptosis, and it was determined that the more GCV incorporated into the DNA,
the faster the S-phase arrest and the higher the levels of apoptosis were.
However, a lower metabolizing variant was successful in vivo. GCV and UCN-01
studies in vivo revealed that each could reduce tumor burden; however, the
combination did not show any enhanced effects.
Taken together, these results offer a significant contribution to molecular
therapeutics by delineation of pathways involved in the drug response and
evaluation of the treatment schemes in vivo.
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CHAPTER I
INTRODUCTION

Colon cancer pathway of pathogenesis
According to the American Cancer Society statistics, colon cancer is the
3rd most frequently diagnosed malignancy in the United States, and it is the 2nd
leading cause of cancer related deaths. Even though many areas of research
have advanced the treatment and improved the lives of patients, forty-two
percent of the 134,560 newly diagnosed patients will die from colon cancer this
year. Progress in understanding the etiology of colon cancer is being made
using the inherited forms of this cancer as molecular models, but unfortunately,
more than 80% of colon cancers are sporadic. Treatment regimes are still largely
based on the use of 5-fluorouracil chemotherapies that have been in use for the
last 40 years as reviewed by (1). It is now commonly believed that all cancers
result from the accumulation of genetic alterations in cellular cancer causing
genes. These alterations are thought to be driven by genetic instabilities.
Colorectal cancer is a multifactoral disease, and while environmental factors are
clearly relevant in the etiology of the condition, genetic factors have a significant
input.
Over the last decade it has become clear that there are at least two major
molecular pathogenic pathways leading to colorectal cancer (CRC): 1)
microsatellite instability, because of defects in DNA mismatch repair (MMR);
and

2

) chromosomal instability, because of defects in the mitotic spindle

This manuscript follows the journal format of Cancer Research.
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apparatus and other genes (2, 3). Approximately 85% of all CRCs are
characterized by genomic instability and loss of normal karyotype, while the other
15% are typically from hereditary nonpolypopsis colon cancer (HNPCC) and
have deficiencies in mismatch repair and have microsatellite instabilities as
reviewed by (4). Interestingly, the pathological and clinical attributes of the
cancers arising out of each of these two pathways are different in that high
frequency microsatellite instability CRCs are more often located in the right
colon, typically diploid, have high grade histology, and cause a prominent
lymphoid reaction (5). This pathway also underlies most cases of HNPCC (6 ),
and leads to cancers that display less aggressive growth characteristics causing
fewer metastases and better overall survival. CRCs with chromosomal
instabilities are characterized by widespread chromosomal deletions and
translocations, whereas those with MSI have ubiquitous DNA mutations (7-9).
Pathogenic mutations in mismatch repair genes have been detected in a
large percentage of families diagnosed with HPNCC, and human mutL
homolog 1 (hMLH1) and human mutS homolog 2 (hMSH2) mutations occur in
90% of the mutations that have been identified so far. Mutations in other
mismatch repair genes like hMSH 6 and hPMS2 may be responsible for
pathogenicity in the mutations not identified (10, 11). Microsatellite instability or
replication error is seen in almost all CRC from patients with HPNCC, and in
approximately 15-20% of sporadic CRC from patients with no reported family
history (10).

Besides point mutations, DNA methylation is also a well-known

cause of the inactivation of MMR genes in HPNCC and sporadic CRC with
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microsatellite instability. One small study of 37 Hungarian sporadic CRC patients
revealed that the most prominent mismatch repair inactivation mechanism was
the hMLH1 promoter hypermethylation. This suggests that may have a role in the
pathogenesis of sporadic colorectal cancer ( 1 2 ).

Gene therapy for cancer treatment
There are many potential contributions of gene therapies for overcoming
the vast obstacles of cancer treatment. Tumors are genetically unstable
rendering them extremely adaptable to environmental changes and resistant to a
variety of treatment schemes. Gene therapy could potentially restore DNA
stability through transfer of normal cell cycle or DNA repair genes. Also, since
tumors can acquire treatment resistance, gene therapies can be delivered to resensitize the tumors to treatments. Similarly, tumors that are not responsive to
standard treatments because they consist of slowly dividing cells can be
transduced by vectors that do not require cellular division for gene delivery and
expression, such as adenovirus, herpesvirus, lentivirus, and chimeric vectors.
Even tumors that have metastasized can be targeted by injectable vectors and
genetic immunopotentiation strategies. Furthermore, better animal models are
being created to fully understand the spontaneous nature of human tumors that
varies significantly from in vitro studies (13). Thus, there are many gene therapy
clinical trials attacking cancer from multiple fronts including: mutation
compensation, molecular chemotherapy, genetic immunopotentiation and viralmediated oncolysis (13).
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HSV-tk/ganciclovir (GCV) gene therapy
The most common molecular chemotherapy system used to date to
accomplish tumor cell killing has been the herpes virus thymidine kinase (HSVtk)
gene combined with the pro-drug GCV. HSV-tk/GCV gene therapy has already
shown initial clinical promise for glioma, mesothelioma, leukemia, and ovarian
cancers (14-18). The rationale behind this system is the use of HSV-tk to
selectively phosphorylate GCV to GCV-monophosphate. Cellular kinases further
metabolize it to GCV-triphosphate, which becomes incorporated into the DNA
and leads to cell death (19-23).

HSV-tk delivery/vectors
The most important step for the success for any gene therapy strategy is
the development of an efficient vector system that is able to specifically deliver
therapeutic genes into targeted cells (24). Gene transfer options include using
nonviral systems such as liposomes or naked DNA or RNA injection, and mainly
viral vehicles including retroviruses, adenoviruses, adeno-associated viruses,
herpes viruses, and lentiviruses (13). Currently, many preclinical and clinical
trials are using retroviral and adenoviral vectors containing the Herpes Simplex
Virus Type-1 thymidine kinase gene (HSV-tk) in combination with the prodrug
ganciclovir (GCV) (14-18). Imaging potential of HSV-tk gene therapy alive is very
promising for future effective cancer treatments. Recently, a study was
developed to use HSV-tk fused to the firefly luciferase gene for real-time
noninvasive in vivo monitoring of the activity of the therapeutic gene in brain
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tumor cells (25). It was determined that bioluminescence can be used reliably for
repetitive quantification of HSV-tk/GCV therapeutic efficacy.

Problems with retroviruses as HSV-tK delivery systems
Worldwide gene therapy trials began to pause or halt after it was
determined that two children developed leukemia after retroviral transduction of
gene therapy. The two youngest recipients of the gene therapy to correct the
mutation in X-linked severe combined immunodeficiency (XSCID) developed Tcell leukemia because the retrovirus inserted in front of LM 02, a known
oncogene (26). The children reportedly responded well to chemotherapy, and
are currently in clinical remission, however the whole ordeal has caused
researchers in the gene therapy community to assess alternatives to using
retroviruses for gene delivery.

The promise of adenoviruses
The most popular method of delivery for gene therapy has been using
retroviruses, however, the use of adenoviruses is gaining popularity because
they are highly efficient in vivo, high titres can be produced, tropism can be
modified, and non-replicative vectors are available (13). Adenoviral delivery
systems hold the promise of future gene therapy approaches because they are
easily manipulated and targetable, and they remain epichromosomal, unlike
retroviruses. This is important because it not only prevents a situation like what
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happened in the X-SCID children, but the gene is not a permanent resident of the
cell and will be cleared.
Recombinant adenoviruses and herpes viruses display high efficiency and
stabilities in vivo, and their replication can be controlled. Despite these
properties, use of adenoviruses currently has severe clinical limitations. It has
been determined that ad-HSV-tk administered locally in mice could leak into the
bloodstream and result in a high level of liver associated toxicity (27) and this
have also been shown in an adenovirus mediated transfer of the HSV-tk gene in
an ascites model of human breast cancer (28)
As mentioned above in the summary of clinical efficacy of HSV-tk, many
attempts have been made to involve the immune system. For HSV-tk/GCV
therapy, “the role of the immune system has been suggested since autopsy
results showed a rapid and centralized hemorrhagic tum or necrosis after injection
of HSV-tk modified tumor cells” (14).

However, many groups have shown

apoptosis induction with GCV treatment, and it has been thought that necrosis
would be the only way to truly stimulate the immune system. Melcher et al in
their 1999 review (29) concluded that enhancement of tum or killing by
involvement of the immune system could be determined by a combination of
factors, including:

1 )the

mechanism and levels of tumor cell cytotoxicity and

2

)

the local environment that exists within and immediately surrounding the dying
tumor. Presumably, if an immune response is to be raised, the tumor cell killing
must occur under specific circumstances in which the immune system can sense
cell death, and this can be exploited in the design of effective therapies (29).
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The immune response to HSV-tk/GCV therapy will be discussed further in
relation to the in vivo bystander effect on page 9.

Mechanism of GCV-mediated Cell Killing
A precise mechanism for how GCV metabolites lead to tumor cell death
has not been established, and there are likely many cellular processes that need
to be characterized including apoptotic responses, DNA damage pathways, and
regulation of the cell cycle. In vitro, GCV-TP has been shown to be a potent and
preferential inhibitor of mammalian DNA polymerase delta (Ki=2 pM), while the
KjS for DNA polymerase alpha and DNA polymerase epsilon were 80 pM and 140
pM respectively (30). In this same in vitro system, GCV-TP can incorporate into
elongating DNA (30). This incorporation is not a chain termination, but it can
significantly distort decamer duplex DNA(30). In cells expressing HSV-TK, GCVTP is also incorporated into cellular DNA (19, 23). It has been postulated that all
of these incorporation events could lead to enough DNA destabilization for strand
breakage.
Thust et al. have determined in HSV-tk expressing CHO cells that
genotoxicity and apoptosis are late events in the response of cells to GCV,
indicating that the incorporation step of GCV is not decisive for triggering
genotoxicity and apoptosis. In these CHO cells, a structural analog of GCV,
penciclovir, could induce apoptosis with minimal genotoxicity, whereas GCV
exerted higher levels of genotoxicity as revealed by sister chromatid exchange
and clastogenicity assays (31). Furthermore, Tomicic e ta l. showed that GCV-
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induced apoptosis was due to incorporation of the drug into the DNA resulting in
replication-dependent formation of DNA double strand breaks and at later stages,
cell cycle arrest at S and G2/M (32).

Protection of cells against the genotoxic

effects of GCV involved (3-pol-dependent single nucleotide and (3 -pol dependent
long-patch base excision repair (BER) (33). Using the (3 -pol inhibitor prunasin
and the (3 -pol dependent short patch base excision repair inhibitor
methoxyamine, these authors demonstrated that GCV incorporated into DNA
could be subjected to repair.
Because GCV can cause severe DNA instability, Bcl-2 levels were
observed to decrease as caspase 3 and caspase 9 activities increased in GCV
treated CHO cells. Further disappearance of Bcl-2 was due to cleavage of that
protein by caspase-9. Bcl-2 cleavage led to excessive cytochrome c release,
dephosphorylation of BAD, cleavage of PARP, and finally DNA degradation (32).
It appeared that in these cells, GCV-induced apoptosis was stimulated by
activation of the mitochondrial damage pathway that is independent of p53.
Caspase mediated cleavage of Bcl-2 can accelerate the apoptotic process, and
this could explain the high potential of GCV to induce apoptosis (32). HSV-tk
expressing glioma and colon tumor cells treated with GCV demonstrate a G1-S
arrest, and melanoma cells have shown an arrest in S-G2 phase of the cell cycle
(19, 21, 23, 34). Apoptosis occurred following the cell cycle arrest in these cells.
Measurement of sister chromatid exchanges and chromosomal aberrations
revealed GCV to be a very active agent classifying it as a strong clastogen (31,
35).
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Bystander Effect
The bystander effect is the phenomenon that actually propelled HSV-tk
gene therapy into clinical trials.

Moolten et al. were the first to describe the

bystander effect when they found that a 9:1 mixture of HSV-tk negative and HSV
tk positive cells plated at a high density was killed completely after GCV addition
(36). The bystander effect is therefore defined as GCV-mediated death of HSV
tk expressing cells and adjacent HSV-tk negative cells (37, 38). The bystander
effect is extremely attractive for gene therapies because it overcomes the many
issues related to gene delivery efficiencies. A major mechanism for the transfer
of GCV metabolites to neighboring cells was reported to be connexin43 (Cx43)
mediated gap junctional intercellular communication (GJIC), and this transfer of
GCV metabolites occurred within 2-4 hours of GCV addition (39).

However,

McMasters et al. determined that even cells transduced with connexin 43 did not
improve overall bystander effect in all cell lines and that it would not be an
effective gene therapy combination in all situations (40).
Cell to cell contact is not required for all cell lines to achieve significant
bystander effect, and cytotoxicity tests have indicated that various cell lines have
a full spectrum of bystander effects. Interestingly, SW620 cells were more
sensitive to low concentrations of GCV (<1uM), accumulated higher levels of
GCV triphosphate and higher levels of GCV incorporation in DNA compared to
HT29 cells. This difference between SW620 and HT29 responding to GCV has
been observed by other labs as well (39). GJIC has been implicated for many
bystander situations, but this effect is not dependent on GJIC in every cell type.
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This was further confirmed when Drake et al. showed that there can be connexinindependent ganciclovir-mediated killing conferred on bystander effect resistant
cell lines by a HSV-tk expressing colon cell lines. In this study, GCV mono-, di-,
and tri-phosphates could be detected in the culture medium of SW620.tk cells
treated with GCV. These metabolites were most likely effluxed from the
SW620.tk cells, indicating that some kind of mechanism independent of gap
junctions exists for nucleotide uptake into neighboring cells (41).

Distant bystander effect
The efficiency of retroviral transduction of solid tumors for gene therapy
purposes remains low, resulting in genetic modification of only a small fraction of
the tumor cells. Therefore, properties of the bystander effect mentioned in the
previous section, or any strategy that does not require all or most of the cells to
be transduced, represents a significant advantage for therapy. In this context,
the involvement of the immune system for effective tumor eradication is
imperative; therefore, understanding how to manipulate therapy to promote anti
tumor responses by the immune system is a priority for gene therapy
researchers. This has been assessed in many in vivo studies of HSV-tk/GCV
therapies. In one study, one HSV-tk positive tumor was generated
simultaneously with one or multiple HSV-tk negative tumors in different rat liver
lobes such that there was no contact between the resulting tumors. Both the TK
- and TK + tumors regressed after GCV treatment and showed infiltration with
macrophages and T lymphocytes (42). The term distant bystander effect
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involves anatomically separated tumors. Even in chemically induced rat
mammary tumors, a distinct distant bystander effect occurred after treatment with
HSVtk and GCV (43).
HSVtk/GCV therapy demonstrates local and distant bystander effects in a
number of animal tumor models. In B16 melanoma tumor targeted by retrovirus
HSV-tk vectors, cell killing was amplified locally due to the bystander killing
effect. This in vivo killing of B16 cells in the lungs (melanoma metastes) may
then elicit an antitumor immune response that appears to be at least partially
dependent on T-cells since it does not occur in athymic mice (44). Treatment of
HSV-tk expressing B16 cells appears to result mainly in necrotic cell death (45).
Also, an HSVtk-mediated local and distant antitumor effect was observed in
tumors of head and neck origin in athymic mice, and the anti-tumor effect was
reduced when performed in SCID-mice (46). However, in murine hepatocellular
carcinoma cells, the HSVtk gene therapy treatment can induce an immune
response in immunocompetent mice, but not in nude mice suggesting that T-cell
mediated immune responses may be a critical factor for achieving successful
therapy results (47). It was hypothesized that the combination of the HSV-tk
gene with a cytokine would enhance an overall immune response to treatment.
Such cytokines tested include: IL-2, IL-4, IL-12, or GM-CSF (45).
The presence of natural killer (NK) cells within adenovirus/HSVtk and
GCV treated tumors analyzed from an orthotopic mouse model of prostate
cancer were identified. Furthermore, in vivo antibody depletion studies noted
that inactivation of NK cells lessened the impact of HSV-tk and GCV on the
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injected primary tumors and completely abrogated the induced systemic activities
due to HSV-tk and GCV. In contrast, depletion of CD4+ and CD 8 + T cells had
no impact on either activity (48). Immunization of tumor bearing mice with
syngeneic tum or cells prior to injection of HSVtk modified tumor cells prolonged
mouse survival. However, unimmunized mice or mice immunized against HSVtk
modified tumor cells showed little to no progress in survival (49).

HSVtk/GCV and multiple modality approaches
In vivo approaches
Unfortunately in previous clinical trials, a majority of the patients have
experienced minor or no responses to HSV-tk/GCV therapy, while 5-10% have
experienced curative or significant clinical responses. It is not clear why there are
variable responses to treatment. This dilemma has prompted initiatives to
improve the therapies using a variety of modalities. Clinical trials are in need of
synergistic effective therapies, and several attempts are being made to
evaluation combination therapies as shown in Table 1.

In vitro approaches
Immunotherapies could prove to be useful adjuvant therapies with HSV
tk/GCV gene therapy, and many other different approaches for the improvement
of HSV-tk/GCV gene therapy in vitro have shown progress.

A summary of that

research is provided in the Table 2.
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Table 1 Summary o f HSV-tk/GCV clinical trials using multiple modalities
Principle
Combination Gene
Therapy
Target
cancer
Investigator
delivery
delivery
Scott
Tumor
Retrovirus
Intraperitoneal Ovarian
in vitro
Freeman
vaccination
with
Her2/Neu
Radiation
and surgery

Retrovirus
in vivo

Intraperitoneal

Glioblastoma

Bernard
Maria

Acyclovir
and
topotecan

Adenovirus
in vivo

Intraperitoneal

Ovarian

Dirk G.
Kirkpatrick

Mutigene
vector: HSV
tk connexin43 and
TNFalpha

Herpes
simplex
virus

Intratumoral

Glioblastoma
multiforme

L. Dade
Lungsford

Chemothera
py and
radiation

Adenovirus

Intratumoral

Locally
advanced
pancreatic
cancer

Carlo
Fernandezdel-Castillo
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Table 2 Summary of in vitro H S V-tkG C V combination approaches

Combination
approach
TRAIL

TK delivery
mechanism
Stable
transfection

Tumor
immunization

Cell lines/system

Results

Citation

SH-EP
neuroblastoma cells

Increase
apoptosis and
increase
bystander
effect

(53)

KBALB and PA-1
cells

Enhanced
tum or killing

(49)

Topotecan

Adenoviral

Murine MC38 and
human HT-29 Animal
model

Effective in
syngeneic
and xenograft

(54)

Ionizing
radiation

Adenoviral

Prostate cancer

1 lung
metastisis
and | in
tumor
immune cell
infiltrate

(55)

Animal model

Ionizing
radiation

Adenoassociated
virus(AAV)

Hela and HP-2
Xenografts nude
mice head neck
cancer

Effective and
reduces
toxicities of
both
therapies

(56)

Secondary
Lymphoid
tissue
chemokines
(SLC)

Bicistronic
vector
Stable
transfection

B16 murine
melanoma model

Enhanced
antitumor and
strong CTL
recruitment

(57)

Hydroxyurea

Stable
transfection

SW620
HT29
U251

Synergy

IL-2 and GMCSF

Retroviral and
adenoviral

Murine melanoma

Synergy

(59)

Butyrate

Stable

HCT116
SW620

Minor
potentiation

(60)

Camptothecin

Stable

HCT116

Antagonistic

(60)

Taxol

Stable

HCT116
SW620

Antagonistic

(60)

(58)
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Herpes Simplex Virus Thymidine Kinase Variants
Modifications of the wild type HSV-tk1 have been pursued as another way
to improve HSV-tk suicide gene therapy. Black et al generated one TK variant
that mediated markedly enhanced tumor cell killing in vitro and in vivo compared
with wild type thymidine kinase. The variant was reported to have increased
preference for phosphorylating GCV and ACV over the competing natural
substrate, thymidine (50). Specific active site HSV-tk variants were generated
and shown to increase tumor cell killing over the others prostate cancer model
both in vitro and in vivo (51). Furthermore, Kelly E. Mercer, a previous graduate
student in the Drake laboratory, designed, purified, and characterized 16 mutant
HSV-tk enzymes and determined that variants Q7530 and N7530 were GCV
specific kinases (52). All of the variants had lower deoxythymidine
phosphorylation activities relative to GCV phosphorylation, and the Q7530.tk had
higher GCV activity than wild type HSV-tk.
Furthermore, even though there are many reports in the literature
demonstrating the antitumor activity of HSV-tk/GCV, information on the
metabolism and cytotoxic mechanism is sparse. Using a well-characterized
second drug with HSV-tk/GCV could not only potentially improve clinical
treatments, but it could also aid in delineating the molecular mechanism of
HSV-tk/GCV cell killing. Our lab had previously reported that colon tumor cell
lines expressing HSV-tk treated with GCV and the staurosporine derivative,
UCN-01 led to increased induction of apoptosis and cell killing rates compared
with either drug alone (60).
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UCN-01 (7-hydroxystaurosporine)
Staurosporine is a fungal metabolite isolated from Streptomyces, and it
potently inhibits the activity of all protein kinase C (PKC) enzymes(61). Although
staurosporine has been characterized as the “universal inducer” of apoptosis in
vitro (62), animal trials have revealed its lack of clinical efficacy (6 3). This has
prompted efforts to design staurosporine derivatives demonstrating high efficacy
in vivo. (As reviewed in (64)) UCN-01 is one such derivative (63), and has shown
great clinical promise. UCN-01 is being used as a single agent for the treatment
of cancers such as lymphoma and melanoma, (www.clinicaltrials.gov) However,
since UCN-01 was found to have a prolonged pharmacological half-life due to its
affinity for alpha-1-acid glycoprotein in the blood (65), the majority of these trials
are using UCN-01 in combination with other chemotherapeutic drugs, and a
summary of those trials is provided in Table 3.
Recently, Sparreboom et al. reported extensive binding of UCN-01 to
alpha-1-acid glycoprotein (AAG) after obtaining pharmokinetic data from a group
of 41 cancer patients receiving UCN-01 as a 72-hour intravenous infusion. This
may partially explain the fact that UCN-01 has had a small volume of distribution
and slow systemic clearance. Furthermore, it was determined that measurement
of UCN-01 plasma concentrations is a poor representation of pharmacologically
active fraction of unbound drug. (66)
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Table 3 Summary o f UCN-01 clinical trials from actively recruiting through
recently completed, (www.clinicaltrials.gov)
Clinical Trial
Target cancer
Actively Recruiting as of
November 2004
UCN-01 and Fluordabine
UCN-01 single agent
UCN-01 and Topotecan

UCN-01
UCN-01
UCN-01
UCN-01
UCN-01

and Irinotecan
and carboplatin
and prednisone
single agent
and cisplatin

Lymphoma and Leukmia
Relapsed T-cell Lymphomas
Recurrent, Persistent, or Progressive
Advanced Ovarian Epithelial, Primary
Peritoneal, or Fallopian Tube
Advanced solid tumors
Advanced Solid tumors
Lymphoma
Metastatic melanoma
Advanced solid tumors

No Longer recruiting__________________________________________
UCN-01 and Cytarabine
Refractory or Relapsed Acute
Myelogenous Leukemia or
Myelodysplastic Syndrome
UCN-01 and cisplatin
Advanced or metastatic solid tumors
UCN-01 and fludarabine
Chronic Lymphocytic Leukemia or
Lymphocytic Lymphoma
Completed___________
UCN-01 and Topotecan

UCN-01 and fluorouracil
UCN-01 and fluorouracil
UCN-01 and gemcitabine
UCN-01 and Fluorouracil and
Leucovorin
UCN-01 single agent
UCN-01 and Fluorouracil and
Leucovorin
UCN-01 continuous infusion
single agent_______________

Recurrent Ovarian Epithelial Cancer,
Fallopian Tube Cancer, or Primary
Peritoneal Cavity Cancer
Metastatic pancreatic cancer
Advanced or refractory solid tumors
Unresectable metastatic pancreatic
cancer
Metastatic or unresectable solid
tumors
Lymphoma and Leukemia
Dose Determination
Breast, lymphoma, and prostate
cancers
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UCN-01 molecular mechanism
UCN-01 can induce cell cycle arrest at the G1 checkpoint, but it can also
abrogate cell cycle arrest induced by cytotoxic DNA damaging agents like cis
platin, araC, or ionizing radiation, UCN-01 has been shown to abrogate S or G2
cell cycle arrest and promote tumor cell death (64, 67). This property has been
attributed to the fact that UCN-01 is a potent inhibitor of Chk1 (IC so=5-1 1nM) but
not Chk2 (IC50>1000nm) (as reviewed by (68)). One function of Chk1 is to
phosphorylate the cdc25c phosphatase at residue Ser216 (69, 70). The
phosphorylated cdc25C is recognized by a 14-3-3 protein and forms a complex
that is sequestered in the cytoplasm (69-71) that prevents premature cdc25cmediated dephosphorylation (and activation) of cdkl/cyclinB. The
phosphorylated form functions to maintain cells in G2 arrest following DNA
damage (72). Thus, a current model is that the inhibition of Chk1 by UCN-01 in
DNA damaged cells (i.e. G2 phase arrest) leads to activation of cdc25C
phosphatase, subsequent dephosphorylation of cdkl/cyclinB, and accelerated
tumor cell death due to abrogation of the G2 checkpoint and entry into mitosis
(73-75).
UCN-01 is commonly categorized as a PKC or CDK (cyclin dependent
kinase) inhibitor, but it is unlikely that interference with those protein classes are
responsible for all the reported effects that UCN-01 has on cells. UCN-01 is a
potent inhibitor of PDK1 (phosphatidlyinositol dependent kinase 1), and unlike its
parent compound staurosporine, the 7-OH group generates direct and watermediated hydrogen bonds with residues in the active site of PDK1 (76), and
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therefore directly interferes with the PDK1-AKT survival signaling pathway (77).
UCN-01 has also been shown to inhibit the RAF/MEK and AKT pathways in
leukemia cells (78), and it has been reported to inhibit nucleotide excision repair
in response to DNA damage caused by cisplatin by attenuating XPA and ERCC1
nucleotide excision repair proteins in chronic lymphocytic leukemia lymphocytes
(79). In human ovarian tumor cells, UCN-01 inhibits the cisplatin-induced
ubiquitination and shift of RNA polymerase II (RNAP II) from the
hypophosphorylated Ila to the hyperphosphorylated No, without affecting basal
levels of those forms of the RNAP II CTD (c-terminal domain). This suggests
that UCN-01 is inhibiting some of the kinases involved in the conversion that is
important for ubiquination of RNAP II and its subsequent degradation (80).
In colon cancer cells (HT-29), UCN-01 markedly reduced the expression
of B c I-X l while enhancing the level of p38 MAPK, and the overexpression of BclXL significantly blocked the apoptosis induced by UCN-01 (81). Since UCN-01
can block the phosphotransferase activity of many kinases by preventing access
of ATP to its binding site on the enzymes, several proteins exhibiting kinase
activity involved in double strand break repair could also be inhibited by UCN-01.
Currently, only the combination of UCN-01 and camptothecin has been shown to
induce DNA double strand breaks in p53 mutant tumor cells, but not in normal
p53 positive epithelial cells (82). UCN-01 has been shown to sensitize a
lymphoma patient to a high dose chemotherapy cocktail, EPOCH II (etoposide,
prednisone, vincristine, cyclophosphamide, doxorubicin) (83). In addition,
multiple fresh surgical specimens obtained from gastric and colorectal cancer
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patients also appear to be particularly sensitive to UCN-01 treatment, and this
response to UCN-01 is more cytotoxic to conventional chemotherapies such as
mitomycin and cisplatin (84). A summary of UCN-01 combination approaches
that have been reported to enhance cell killing or tumor reduction is provided in
Table 4.
The drugs in combination with UCN-01 have a full spectrum of
mechanisms of enhanced cell killing.

W e have hypothesized that UCN-01

effects cell cycle, checkpoints, and cell death and DNA damage signaling
mechanisms. In the remaining sections, an overview of those areas will be
presented.

Cell cycle and DNA damage repair
Cell cycle checkpoint signaling networks monitor the successful
completion of each event during eukaryotic cell cycle progression prior to
proceeding into the next phase. Cells can temporarily arrest their metabolic
activities associated with DNA replication of mitosis at these checkpoints to allow
for repair of any damage, dissipation of exogenous cellular factors, or for the
accumulation of essential nutrients and growth factors. The basic outline of cell
cycle progression is as follows: Gi is defined as the phase of the cycle where
cells develop a metabolic state suitable for growth and division; S-phase is where
the cells are committed to doubling their genomic information; G 2 phase is where
the cells prepare for final checks before commitment to mitosis and subsequent
division into two daughter cells. Signaling may also activate pathways leading to
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Table 4 Summary o f UCN-01 combination approaches in vitro and in vivo
Compounds combined
with UCN-01 resulting in
increased cell killing or
Cell line/ model
Citation
tum or reduction
Gemcitabine
Human myeloid leukemia
(85)
Cisplatin
Cisplatin
Cisplatin
Camptothecin

A549
CHO
Human breast cancer cells
MDA-MB-231
HMEC
HE6

(79)
(86)
(87)
(82)

Camptothecin

HT29
HCT116
MCF-7
A431
HCT116
MCF-7
A431 Murine Leukemia
U937
HL-60
HT-29
U937
U937
HL-60
U937
HL-60
Leukemia

(88)

SK-GT5
Normal and leukemic
lymphocytes
PC-3
A549

(94)
(95)

Tamoxifen

Human breast cancer in vitro and
in vivo

(97)

Radiation
Danazol and
mifepristone
ATF-2 derived peptides
GCV

Non-small cell lung carcinoma
Hormone responsive breast
cancer
Melanoma
SW620.tk

(98)
(99)

Mitomycin C

Mitomycin C
Ara-C
Ara-C
TRAIL
17-AAG
MEK Inhibitors PD98059
And U0126
Nucleside analogs:
gemcitabine ara-c, f-araA, FMdC
5-Fluorouracil
4-HC
UV
Perifosine
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programmed cell death if the damage cannot be properly repaired, (as reviewed
by (101))
A sophisticated DNA damage response pathway sensing aberrant DNA
structures has evolved in mammalian cells to ensure their long-term survival.
Activation of this pathway causes stimulation of DNA repair complexes, and cell
cycle arrest, and if the damage cannot be repaired, the cell is committed to
apoptosis. The eukaryotic strategy to handle damaged DNA can be split into
three stages: the recognition of injured DNA, a period of damage assessment,
regulated by checkpoints, and the implementation of the appropriate responseDNA repair or cell death. These responses are not activated in a linear fashion
because damage recognition elicits multiple synchronous signals that can trigger
both repair and apoptotic processes, (as reviewed in (102)).
Three robust DNA damage repair systems have evolved for the protection
of eukarytotic cells including: nucleotide and base excision repair (NER and
BER), mismatch repair (MMR), and double strand break (DSB) repair. Double
strand breaks are the most lethal, as they are not all accurately repaired due to
non-homologous end rejoining. In contrast, altered bases and single strand
breaks are more readily repaired. Secondary effects of DNA damage can arise if
the damage is not repaired leading to DNA fragmentation, deletions, and
chromosomal rearrangements, (as reviewed in (102).
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Excision Repair
Nucleotide excision repair (NER) is primarily used to excise bulky adducts
crosslinked to the oligonucleotide, and oxidative DNA damage is also repaired by
NER. This mechanism of repair is very flexible and it corrects damage that both
distorts the DNA molecule and alters the chemistry of the DNA molecule. This
repair involves damage recognition; binding of a protein complex at the damaged
site; double incision of the damaged strand several nucleotides away from the
site of damage; exicision of the damage followed by filling in by a DNA
polymerase and ligation (103). Base excision repair (BER) is the main system
for removing small base damages including oxidative DNA lesions. In contrast to
NER, BER employs DNA lesion-specific glycoslyases to recognize and bind to
the damaged site, and then they remove the base. The resulting abasic site is
cleaved to remove the 5-1-deoxyribose phosphate and the one-nucleotide gap is
closed by DNA polymerase (104, 105).

Mismatch repair (MMR)
The DNA mismatch repair system is involved in the correction of
base/base mismatches and insertion/deletion loops arising during replication,
and monitors closely the newly synthesized DNA strand for incorrect or
mismatched bases which are removed and replaced by the correct equivalents
(11). DNA excision repair and MMR overlap to some extent, and MMR is not
only involved in the repair of chemical damage to DNA but is also involved in
processing of recombination in intermediates. Both hMSH2 and hMLH1 (missing
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in the HCT116 colon tumor cell line) have recently been shown to be a part of a
super complex of BRCA-1 associated proteins also containing MSH6, ATM,
NBS1, and MRE11, and this complex is believed to act as a DNA damage sensor
and to participate in the recognition and repair of aberrant DNA structures (106,
107). Detection of this repair complex after DNA damage would also reveal the
level of damage and potential mechanism of drug action.

Double Strand Breaks and associated repair mechanisms
Double strand breaks are a severe threat to the maintenance of genomic
integrity. They can be produced endogenously by DNA replication, through
processes such as V(D)J recombination and meiosis, some chemotherapeutic
drugs, hydroxyl radicals, ionizing radiation, and unrepaired single strand breaks
(as reviewed in (108)). If left unrepaired, DSBs can result in permanent cell cycle
arrest, induction of apoptosis, or mitotic cell death caused by loss of genomic
material. The two main strategies to repair DSBs are homologous recombination
repair (HRR) and non-homologous end joining (NHEJ) (108).

Nonhomoloqous end joining (NHEJ)
The major pathway for repairing DSBs in mammalian cells is NHEJ which
repairs broken DNA ends with little or no requirement for sequence homology. It
involves the XRCC4 gene product (109), DNA ligase IV (110) and the DNAprotein kinase (DNA-PK) holo-enzyme (111), consisting of the DNA end-binding
heterodimer Ku70/Ku80 and the catalytic subunit DNA-PKcs. Ku70 and Ku80
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bind to free ends, DNA-PKcs associates with Ku-signals (112), NBS and Rad50
stimulates Mre11 exonuclease and they process the DSB, and finally XrCC4
binds to Ku and targets the ligase IV to the break (113). ATM and ATR share
homology in their kinase domains with the DNA DSB repair protein DNA-Pk
catalytic subunit (DNA-PKcs). In vertebrates, Ku serves as the DNA targeting
subunit of DNA-PKcs which together forms the DNA-Pk holoenzyme. The
catalytic subunit alone is ~465 kd, and the c-terminal domain shares homology
with the catalytic domains of proteins in the phosphotidyl inositol 3-kinase-like
family (PIKK). (as reviewed in (108))

Homologous recombination repair (HRR)
HR is an essential DNA damage repair pathway for cell survival, and it is
involved in the repair of DNA double strand breaks and DNA lesions that occur at
replication forks. It involves the genetic exchange between DNA sequences that
share homology. A classical double strand break cuts the DNA strand leaving
two free DNA ends that may both initiate recombination. Also, a double strand
break can arise if a replication fork collides with an unrepaired DNA single strand
break causing a collapsed replication fork, and these DSBs trigger HRR in
mammalian cells even though they only have one free DNA end to initiate the
repair. HRR has also been implicated in the repair of stalled replication forks that
can occur without detectable DSBs (114).
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DNA damage signaling
The sequestration of molecules by scaffold proteins is a familiar concept in
the field of protein signaling and imposes order and substrate specificity on
proteins that are common to several pathways. The existence of such regulatory
supercomplexes within the nucleus would be a necessity given that crucial repair
nucleases cannot be allowed to diffuse freely. Recently, the BASC, BRCA1
associated genome surveillance complex, has been described as a
supercomplex of tum or suppressors and DNA repair proteins (115). Detection of
these foci, which suggests a DNA damage protein supercomplex response,
would help delineate the signalling pathway that potentially indicates double
strand breaks.

Breast Cancer 1 (BRCA1)
BRCA1 is the 220kd protein product of Breast Cancer susceptibility
g e n e l, and it is a major target of a DNA damage response. The DNA dependent
kinases ATM and ATR are known to phosphorylate BRCA1 in response to
ionizing radiation. BRCA1 has been shown to function in genomic stability by
controlling homologous recombination, transcription-coupled repair of oxidative
DNA damage (specifically NER), and cell cycle checkpoints (115). Furthermore,
BRCA1 deficient cells fail to appropriately check in S and G2 after DNA damage
(As reviewed by (116)). BRCA-1 coimmunoprecipitates with a number of DNA
repair proteins including: MSH2, MSH6, ATM, Rad51, and the Rad50-Mre11-
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NSB protein complex, and it is known to localize to nuclear foci with these
proteins after ionizing radiation and UV radiation (117).

Ataxia telangiectasia mutated (ATM) and
Ataxia telangiectasia mutated and Rad 3 related (ATR)
ATM and ATR are crucial in detecting the most lethal type of DNA
damage, the double strand break, and they have distinct but overlapping
substrate specificities including the abilities of both enzymes to target p53 (Ser15) and BRCA1 (Ser-1423). They are both members of the phosphoinositide 3 kinase like kinase (PIKK) family which includes ATM, ATR, and DNA-dependent
protein kinase (DNA-Pk). ATM (350kD) phosphorylates numerous targets that
mediate cell cycle checkpoints and DNA repair including Chk2, 53BP1, and
H2AX (118-120). It is thought that large kinases are required to detect DNA
damage so that they can provide a platform over which other detectors and
repair proteins can assemble (102).

Chk1 and Chk2 protein kinases
Chk1 and Chk2 are ubiquitously expressed serine/threonine kinases and
are critical for signaling DNA damage to cell cycle regulation proteins dependent
on the ATM family of protein kinases (121-123). While the phosphorylation of its
activation loop is not required for Chk1 activation, it is required for the activation
of Chk2. Chk1 functions as an essential component of the G2/M checkpoint
while Chk2 is required at G1/S for at least low dose ionizing radiation. Even
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though the role of Chk1 in DNA damage signalling is not clear, Chk2 is thought to
potentially act through BRCA1. Chk2 is a tumor suppressor and is important for
DNA damage-induced apoptosis, while Chk1 does not have this property (68)

p53 binding protein (53BP1)
53BP1 was originally isolated as a p53 interacting protein using yeast two
hybrid screens (124). It contains numerous (S/T)Q motifs and two C-terminal
BRCT (BRCA1 carboxyl-terminal) repeats. 53BP1 proteins are phosphorylated
in response to gamma IR, and IR causes 53BP1 proteins to rapidly relocalize to
DNA repair foci. These foci also overlap with BRCA1 and gamma H2AX DNA
damage induced foci. Gamma H2AX recruits 53BP1 to nuclear foci and
physically interacts with 53BP1 (120, 125). Mice that are defective for 53BP1 are
radioresistant, immune deficient, and predisposed to cancer. Also, a fragment of
53BP1 co-localizes with autophosphorylated DNA-PKcs at nuclear foci and can
stimulate DNA end joining in vitro both suggesting that 53BP1 could play a role in
NHEJ (as reviewed in (126)).

Histone 2AX (H2AX1
In addition, there is a method to indirectly monitor the presence of
individual DSBs. Within a few moments after the induction of a DSB, hundreds
to thousands of histone H2AX molecules are phosphorylated by DNA-PK in a
chromatin domain several mega base pairs around the break site. Using an
antibody specific for the phosphorylated form, yH2AX, these chromatin
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modifications can be visualized within the cell nucleus by fluorescence
microscopy. Currently, all evidence available points to a direct correlation
between these modifications and the presence of DSBs (127). Recently,
phosphorylation of H2AX was shown to be regulated by acetylation, and this
supports the finding that histone acetylation critically functions in repairing DNA
DSBs (128).
The role of these multiple DNA damage response and regulatory
pathways in cells treated with GCV and UCN-01 is largely unknown, but will be
further evaluated in this dissertation.

Goals of dissertation
Our long-range-goal is to improve HSVtk gene therapy on many fronts by
enhancing or modulating the bystander effect (Cx-43, MRP-4), obtaining tumor
specific gene expression (b-catenin responsive) and delivery of the enzyme with
adenovirus vectors, improving the catalytic efficiency or substrate specificity of
HSV-TK for GCV, and optimizing chemotherapy modalities (UCN-01 + GCV). All
of these research arms for improving HSV-tk gene therapy are interrelated, and
they have each generated useful data and tools for the specific angle of the
project that is the subject of the dissertation.
The objective of these studies was to identify the molecular basis of the
synergistic cell killing of the GCV and UCN-01 combinations by evaluating cell
death and DNA damage response mechanisms.

The central hypothesis for

the our research was that the S-phase arrest and DNA damage pathway initiated
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after GCV treatment sensitizes the cells to the treatment with UCN-01 because it
prevents repair of GCV damage and causes further damage itself. A better
understanding of the individual and synergistic mechanisms of the actions of
GCV and UCN-01 could lead to the design of improved gene and
chemotherapeutic combinations. Potentially, new molecular targets will be
identified for further characterization and/or drug targeting.

A i m # 1:
Evaluate the role of the cell cycle, cell death mechanisms, and proteomic
effects of cells treated with HSV-tk/GCV and UCN-01 drug combinations.
HSV-TK expressing tumor cells were synchronized, drug treated, and evaluated
by DAPI staining, western blotting for cell cycle proteins, DNA metabolic labeling,
flow cytometry, caspase assays, and bromodeoxyuridine labeling. Surface
Enhanced Laser Desorption Ionization Time of light mass spectroscopy and two
dimensional gel electrophoresis were used as global proteomic approaches to
study cancer cell hallmarks and proteome responses to GCV and UCN-01
treatment combinations.

Aim # 2:
Determine the signaling network and cause of DNA damage after treatment
with GCV, UCN-01, and the combination. Immunofluorescence and western
blotting of proteins involved in the DNA damage-signaling network, pulsed field
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gel electrophoresis, and specific DNA repair inhibitors were used pinpoint the
cause and execution of DNA damage and signaling.

Aim # 3:
Evaluate wild type and enhanced function HSV-tk variants in in v itro and in
vivo TRAMP model combined with UCN-01.

Similar methods used in Aim #1

were used to characterize the cell cycle and cell death mechanisms of HSV-tk
variants. Transgenic adenocarcinoma murine prostate (TRAMP) cells were
stably transfected with the TK variants and tested in an in vivo TRAMP model in
addition to UCN-01 and GCV drug combinations. Animals will be injected with
tumor cells and treated with the drugs after tumors are palpable. These initial
animal studies will include tumor measurements and H&E staining of the excised
tumors.
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CHAPTER II
MATERIALS AND METHODS
Materials
UCN-01 was obtained from the Developmental Therapeutics Program,
National Cancer Institute, National Institutes of Health. 10mM stocks were stored
in DMSO at -2 0 C and 30-1000nm were used in assays; Ganciclovir was
obtained by prescription and stocks were made in water and concentration
determined UV adsorbance. Concentrations used were between 0.1-100pm.
Lactacvstin was from Sigma (St. Louis, MO) and 10pM were used in assays;
Caffeine was from Sigma (St. Louis, MO) and 1-6mM concentrations were used
in assay; NU7026(2-(morpholin-4-vl)-benzolhlchromen-4-one).a DNA-Pk specific
inhibitor, was from Calbiochem(San Diego, CA) and 8.9 mM stocks were made in
DMSO and stored at -20°C;10-100 pm was used in assays; Methoxvamine was
from Sigma (St. Louis, MO) and 1.2 M stocks were made in water and stored at 20°C; concentrations between 3-20 mM were used. Nitrocellulose blotting
membranes were from Schleicher and Schuell (Keene, NH); MTT (3-(4.5dimethylthiazol-2-vl)-2.5-diphenyltetrazolium bromide) was from Sigma (St.
Louis, MO); BrDU metabolic labeling kit was from BD Biosciences (San Diego,
CA); Caspase Activation Kit was from Clontech (San Diego, CA); ApopTag™
apoptosis kit wasfr om Serologicals Corporation (Norcross, GA).
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Antibodies for western blots and immunofluorescence microscopy
Primary Antibodies:
Cyclin B and cvclin A were from Pharmagen (Hauppauge, NY); Cdk1 and cdk1-p
were from

Cell

Signalling

(Beverly,

MA);

Bcl-XL was from

Transduction

Laboratories, Inc. (Lexington, KY); Cdc25C, Chk1. and Chk2 were from Santa
Cruz Biotechnology (Santa Cruz, CA); Phospho-Chk1 (Ser345) and PhosphoChk2

were

from

Cell

Signalling

Technology

(Beverly,

MA);

vH2AX

(phosphorylated Histone 2AX) was from Trevigen (Gaithersburg, MD); BRCA and
53BP1 were from Bethyl Laboratories (Montgomery,TX)

Secondary Antibodies:
HRP-coniugated goat-anti-rabbit and qoat-anti-mouse secondary antibodies were
from Bio-Rad (Hercules, CA). Alexa Fluor 488nm and 546nm goat anti-mouse
and anit-rabbit IqGs were from Molecular Probes/lnvitrogen (Eugene, OR)

Cell Lines
HSV-TK Expressing Cell Lines
The three HSV-TK-expressing human colon tumor cell lines and one HSVtk- expressing human breast cancer cell line (SW620.TK, HT-29.TK, HCT116.TK, and MCF-7.tk) were maintained in RPMI 1640 supplemented with 10%
FBS. Each HSV-TK expressing cell line was previously generated following
transfection and G418 selection with a bicistronic HSV-TK/neo Moloney Murine
Leukemia Virus-derived plasmid, pLTKEN, as previously described (23).
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cell line was characterized for sensitivity to GCV cell killing and HSV-TK
expression (23).

Normal Colon Cell Lines
CSC-1 and NCM 460 cells were obtained from InCell™ Corporation (San
Antonio, TX) and maintained in InCell™ M3:10 media.

Cell Viability Assays
The cell line of interest was seeded in 96 well plates in 0.1 ml media
(7,000 cells/well). After 48 hrs, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) (50 pg/well) was added for 1.5 hours, followed by
DMSO (dimethyl sulfoxide) solubilization of the cells and absorbance readings at
540 nm (129). Data were recorded in Excel and graphed relative to percent of
untreated control values.

Clonal Dilutions
Cells (1X105) were seeded in 24 well plates, and after 24 hours, different
drug treatments were added. After another 24 hours, the media was removed,
and the cells were rinsed and treated with trypsin. After addition of 1 ml fresh
medium, each of the wells was then sequentially diluted from 1:10 to 1:10,000 in
1ml of medium in a separate 24-well plate. After 7 days, surviving cell colonies
were fixed in 100% methanol, stained with 0.1% methylene blue and counted.
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Clonal Survival Assays
2000-3000 cells were plated/ well in 24-well plates. Different drug treatments
were added 24 hours later. After 7 days, surviving cell colonies were fixed in
100% methanol, stained with 0.1% methylene blue and counted.

Cell synchronization
HSV-TK expressing cells were synchronized by the double thymidine
block method (130). Initially, 105 cells were plated in a 60mm plate. The
following day, 2 mM thymidine was added to each well for 16 hours. After
extensive rinsing of the cells, fresh media (without thymidine) was added to each
well for 9 hours, followed by subsequent addition of 2 mM thymidine for an
additional 16 hours. Following this second thymidine block and rinsing, cells
were incubated in media plus or minus the chemical or drug of interest.

Radiation exposure
Double thymidine blocked SW620.tk cells (2.4X106) were resuspended in
6 mis of media in 15ml conical tubes and were exposed to 4 Gy or 12 Gy of
radiation via a Cesium-137 source in a lead chamber apparatus. After radiation,
cells (0.4X106) were seeded in 6-well plates. Cells were treated with either
radiation only or an addition of UCN-01. Control cells were taken from the cell
suspension prior to radiation.
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Cell cycle analysis
For cell cycle analysis, cells were fixed in 70% ethanol, stained with
propidium iodide and analyzed by flow cytometry on a FACSCalibur instrument
(Becton Dickinson, Mountain View, CA) as previously described (23).

Western Blot Analysis
Prior to loading onto the SDS-PAGE gel, 1ul was used in a Bradford assay
(BioRad) to determine protein concentration. Pelleted cells were resuspended in
75ul of dH20 and then 25ul of sample loading buffer (4M Urea, 20mM DTT,
100mM Tris pH 8.0, 4%SDS and Bromophenol Blue) were added immediately
after samples were resuspended in the water. Samples were boiled for 5
minutes prior to loading. Usually about 80-120ug of protein were added per well.
Equal loading was measured by protein loaded, gel staining, and p-actin western
blots. 10% SDS-PAGE gels were used for western blots of proteins between 30
and 80kd. Gels were run overnight at 8mA per gel. Proteins were transferred to
nitrocellulose (Schicher and Schuell) at 100V for 1 hour at room temperature.
Michelle Wezeman was responsible for cdc25C, cyclin B and Cdk1/Cdk1-P in the
SW620.tk cell line westerns shown in Figure 5.

Metabolic Labeling with Bromodeoxyuridine (BrDU)
SW620.tk or SW620 parent cells (2.7X105) were plated in 60mm plates
with 0 or 10pM BrdU, and the next day 2mM thymidine was added. After 16
hours, the thymidine was rinsed from the plates 2 times, and media and BrDU
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were added for 9 hours outgrowth followed by the second addition of 2mM
thymidine for the plates not pulsed. 16 hours later, the plates were rinsed 2
times and the preincubation BrDU was removed and the media and drugs were
added to the plates. BrDU was only added to the plates without the
preincubation for a 2-hour pulse before their harvest. HSVtk variants cells lines
were not synchronized, and were only pulsed with BrDU.
106 cells were harvested for flow preparation and resuspended in the BD
Cytofix/Cytooperm buffer and incubated for 15-30 mins at room temperature.
Cells were washed with 1ml of the BD/Perm/Wash buffer and centrifuged at 200300g for 5 minutes. Cells were then resuspended in BD cytoperm plus buffer
and incubated for 10 min on ice and washed as mentioned above. Cells were re
fixed with Cytofix/Cytooperm buffer and washed. Then the pellet was
resuspended with 10Oul of DNAse (30ug per sample) and cells were incubated at
37C for 1 hour. Cells were washed and then stained with 20pl of 7-AAD solution.
Also, 1 ml of staining buffer was added to each tube to further resuspend the
cells. Cells were analyzed by flow cytometry. Analysis assistance was provided
by Dr. Richard Britten and Ellen Jing in the flow cytometry facility.

Caspase-3/DEVDase Assays
SW620.TK cells were double thymidine synchronized, then released into
media alone or media containing 10 pM GCV, 0.3 pM UCN-01 or 10 pM GCV/0.3
pM UCN-01. At different time points cells were removed and assayed for
caspase 3-like activity using a Clontech colorimetric kit with DEVD-pNA cleavage
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from protein extracts derived from 2 X 106 cells. Each condition was done in
triplicate. DEVDase activities were quantitated at 405 nm. Dr. Richard Drake
carried out these experiments.

DAPI-staining
SW620.TK cells were plated in 8 well chamber slides (2 X 105/well),
double-thymidine blocked, and released with media or the indicated GCV and
UCN-01 combinations for 24 hrs. The cells were fixed in methanol and stained
with 1pg/ml DAPI, and visualized with a Zeiss fluorescent microscope on 40X
magnification. The areas of at least 10 random nuclei per slide were quantitated
using Metamorph imaging software.

Cellular Apoptosis Detection
The ApopTag™ apoptosis kit was used to detect the amount of apoptosis
of HSVtk variants treated and untreated with GCV. 200,000 cells were seeded
on glass slides and were incubated in 100 mm dishes. Cells were double
thymidine blocked prior to 20pM GCV addition for 24 hours. Cells were fixed in
1% paraformaldehyde and permeabolized in 1% Triton X100, and were prepared
according to manufacturer’s protocol. A detailed explanation of the use of this
protocol is provided in section C. After the entire protocol was completed, cover
slips were mounted onto glass slides with Vectashield™ mounting medium and
allowed to air-dry overnight before viewing and quantitation of the number of
apoptotic cells per field at a 25X magnification.
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Metabolic labeling assays
Cells were plated (5 X105/well) in triplicate in a 6-well plate. The following
day, cells were incubated for 18 hours in 1.5 ml of media containing 1 pCi
[3H]GCV (17.4 Ci/mmol) (Moravek) and 1 pM unlabeled GCV alone, or in
combination with 0.3 pM UCN-01. Nucleotides were extracted with 70%
methanol, and the supernatants were separated on PEI-cellulose thin layer
chromatography plates with 1M LiCI as previously described (23). The methanol
insoluble pellet was extensively washed with phosphate buffered saline, then
resuspended in minimal 0.1 ml water, and quantitated by scintillation counting as
an indicator of DNA incorporation (23). Dr. Richard Drake carried out these
experiments and was authorized by the Radiation Department of Occupational
Health and Safety at the University of Arkansas for Medical Sciences.

Immunofluorescence
80,000 cells were seeded onto each well of a 2-well Permanox slide.
These cells will be then double thymidine blocked and released into media alone,
10pm GCV, 0.3 pM UCN-01, or 10pM GCV/0.3 pM UCN-01 for 12 hours. Cells
were first washed with PBS two times and then were fixed with 2%
paraformaldehyde at room temperature for 12 minutes; washed three times with
PBS and then permeabolized with 0.5% Triton X-100 for 5 minutes at room
temperature. Then, cells were washed four times with PBS and incubated with
the appropriate antibody in 3% bovine serum albumin (Sigma) overnight at 4°C in
a humidified chamber. The next day, the primary antibody was removed and the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

40
cells were washed with 1%PBS-Tween 3 times. The secondary antibody was
diluted in 3% BSA and incubated in the wells for 1 hour at room temperature in a
humidified chamber in the dark. Cells were then washed 2 times with 3% BSA
and 2 times with PBS. Cover slips were mounted with Vectashield™ mounting
medium and were allowed to dry for 1 hour in the dark. Images were captured
using a Zeiss confocal microscope.

Pulsed Field Gel Electrophoresis
For each drug treatment and time point, cells were spun down at 200g for
5 minutes and resuspended in ice-cold PBS. This procedure was repeated 3
times. The final cell suspension should be approximately 3X 106 cells/ml; 300pl
of this suspension was mixed with 300pl molten 1% InCert agarose (FMC,
Rockland, ME, USA; 1% in solution with PBS) in a 15 ml conical tube. The cellagarose mixture was pipetted into a plug former on ice and refrigerated for 15
minutes. The formation of agarose plugs of whole cells for DNA analysis
prevents shearing of the DNA prior to electrophoresis. Plugs were then removed
from the formers, and incubated in ESP solution (0.5M EDTA, 1% w.v. sarcosyl,
and 1mg/ml proteinase K; pH 9) for 2 hours at 4°C and at 49°C for 20 hours.
Then, the plugs were washed in TE buffer (10mM Tris-HCL 1mM EDTA, pH 7.5)
three times, each for one hour. The DNA in the plugs was separated by Pulsed
Field Gel Electrophoresis in a 12.5 X 14 X 0.5 cm electrophoresis grade gel
(0.5% solution in 0.5X TBE buffer plus Ethidium Bromide). Plugs containing the
DNA from ~9 X 104 cells (~5 pg) were loaded into each well and sealed with
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0.5% agarose. The gel was run for 24-48 hours on a CHEF-DR II (BioRad,
Richmond, CA) operating at 40 V (~1.21 V cm '1) with a switch time of 4500
seconds. The 0.5X TBE buffer was re-circulated by a temperature-regulating unit
maintained at 16°C (131).
For the alkaline elution studies, plugs were incubated in alkaline buffer
(50mM NaOFI; 1mM EDTA (pH 12.5) adapted from (132)) for 2 hours prior to
loading in to the gel with gel electrophoresis parameters the same as for neutral
elution as described above.

Images were captured using a Kodak gel imaging

system. All plugs were run on another agarose gel using a standard
electrophoresis unit at 1 hour for 45 volts to detect DNA laddering indicative of
apoptosis that may be responsible for PFGE elution.

Surface enhanced Laser Desorption Ionization Time of Flight (SELDI-TOF)
Mass Spectroscopy
Cell lysates for SELDI-TOF
SW620.tk cells (5X106) were synchronized and treated with media, 10pM
GCV, 0.3pM UCN-01 or 10pMGCV/0.3pM UCN-01.

Cell lysis buffer (20mM

Hepes pH 7.5 and 1% Triton X 100 1 pi aprotinin) was added to pelleted cells and
then cells were sonicated for 1 minute and spun at 4°C for 10 minutes at 14,000
rpm, and then the supernatant was placed into fresh tubes.
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Nuclear Lysates
SW620.tk cells (2 X106) were plated in T-75 tissue culture flasks,
synchronized, and drug treated as previously described. After 24 hours, the cells
were harvested. The nuclear fractions from the cells were separated from the
cytosol and membranes and enriched by differential centrifugation using NE-PER
reagents from Pierce (Rockford, IL).

Protein Chip Preparation and Protein Sample loading
Strong Anion Exchange (SAX) Protein Chips were prepared by adding
20mM Tris pH 7.5 with 0.1% Triton-X to each well, shaking for 5 minutes at room
temperature, and discarding of the buffer, (repeated once). Dilutions (1:25 or
1:50) of the samples were made in the Protein Chip buffer prior to placing the
samples on the chips. After the bioprocessor was assembled, 200ul of the
appropriate Protein chip buffer was added to the sample wells and placed on
shaker for 5 minutes. This was done two times. 10OpI of the diluted sample
were added to the chips and the processor was shaken overnight to allow
specific binding. The liquid was discarded after the overnight incubation and
therefore anything unbound was removed. 200pl of the appropriate Protein Chip
buffer was applied to the chips and removed after 5 minutes of shaking.
(repeated once) Chips were then rinsed with HPLC grade water twice and were
air-dried at least 2 hours. Sinapinic Acid (0.5 mg SPA), the energy adsorbing
molecule, was resuspended in 100pl 1% trifluoroacetic acid and 100pl of
acetonitrile. SPA (0.5pl) was added to each spot on the protein chip twice.
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Spectra
A surface-enhanced laser desorption/inoization (SELDI) PBS-II mass
reader from Ciphergen Biosystems was used to generate the protein spectra,
mass ranged from 0-20000 daltons. The protein masses were calibrated
externally using purified peptide standards. Cell lysates were read using the
lowmass method: Machine settings: Detector voltage 1850-1900 volts; high
mass to 200000 daltons; optimized from 3000 daltons to 50000 daltons; starting
laser intensity at 220; starting detector sensitivity to 7; focus lag time at 900 ns;
SELDI acquisition parameters set to 23, delta to 4, transients per to 12 ending
position 83. The spectra were analyzed with the Ciphergen ProteinChip®
software (version 3.1) and normalized using total ion current. Peaks were
identified using auto identify from 2000 daltons to 100000 daltons.

Two Dimensional gel electrophoresis (2D gel electrophoresis)
Cell lysates
Initially, 1X106 HSV-tk expressing cells were plated in 100mm2 plates and
treated with GCV, UCN-01, or the combination. After 24 hours treatment, the
cells were harvested and counted. 100pl of BioRad Rehydration/sample buffer
was added for every 100,000 cells, and typically 0.5 X 106to 1X 106 cells for
each condition were harvested. Equal amounts of protein from the cell lysates
were diluted again in rehydration/sample buffer for a total of 200pl including 5 pi
of an 2D gel-electrophoresis standard (BioRad). Since the reagents in the
rehydration/sample buffer interfere with standard protein assays, we used the
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RC-DC protein assay kit from BioRad to determine protein concentrations from
the cell lysis step. Typically 20pg to 200pg proteins were loaded on the IPG
strips. The samples were allowed to hydrate using either the pH 3-10 or pH 5-8
IPG strips for 11-16 hours, and then the strips were placed in the isoelectric
focusing unit.

Nuclear extracts
Cells were plated and synchronized in 100mm2 plates and treated with
GCV, UCN-01, or the combination for 24 hours. Cells were then scraped into ice
cold PBS and spun down at 1000 rpm for 5 minutes. 5X106 cells were pelleted
and resuspended in 200pl ice-cold buffer 1 (10mM HEPES (pH 7.9) 10mM KCI,
0.1 mM EDTA 0.1 mM EGTA 1mM DTT and protease cocktail inhibitor from
Invitrogen). Cells were chilled on ice for 15 minutes, and then they were lysed
with 0.6% Nonidet p-40 derivative followed by mixing by inversion several times.
Nuclei were pelleted at 200g for 5 minutes at 4°C. The supernatant was
decanted and the pellet was resuspended in ice-cold buffer 2 (20mM HEPES (pH
7.9) 0.4 NaCI, 1 mM EDTA 1mM EGTA 10% v/v glycerol, 1mM DTT and
Protease Cocktail from Invitrogen). Nuclei were resuspended gently and lysed
by shaking for 30 minutes at 4°C. The lysates were then centrifuged at 12000g
for 10 minutes at 4°C, and were stored in dilute protease cocktail and snap
frozen on dry ice (133). 20pg of nuclear extract was diluted in
rehydration/sample buffer for focusing.
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Isoelectric Focusing
A Protean IEF Cell (BioRad) was used for the first dimension isoelectric
focusing of IPG loaded strips. A standard focusing program began at 250 volts
for the first 15 minutes, the next 2.5 hours the voltage was set to reach 8000
volts. The 8000 volts was maintained until a total of 35,000 volt hours occurred.

Gel electrophoresis
Following first dimension isoelectric focusing, the IPG strip was
equilibrated in Buffer 1 (6M urea, 0.375 M Tris, pH 8.8, 2% SDS, 20% glycerol,
and 2% w/v DTT) for 15 minutes in a plastic tray in an orbital shaker and then for
another 15 minutes in buffer 2 (6M urea, 0.375 M Tris, pH 8.8, 2% SDS, 20%
glycerol, and 2.5 % w/v iodoacetamide).

The strips were then loaded on an 8-

16% gradient Criterion precast gels and placed in a Criterion cell (BioRad). Two
gels at a time were run in the cell for 1 hour at 200V to completion.

Protein Gel Staining
A SilverQuest™ (Invitrogen) silver staining kit was used according to
manufacturer’s basic protocol. Gels were stored in water indefinitely.

2D Spot Identification by LC-MS/MS
In-gel Trypsin Digest
Gel slices were cut into 1-2 mm cubes, destained with the SilverQuest™
destaining kit (Invitrogen) as per manufacturers instructions and incubated in
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100% acetonitrile for 45 minutes. The material was dried in a speed-vacuum and
rehydrated in a 12.5 ng/pL modified sequencing grade trypsin solution and
incubated in an ice bath for approximately 45 minutes. The excess trypsin
solution was then removed and replaced with 40-50 pL of 50 mM ammonium
bicarbonate, pH 8.0. The digest was allowed to proceed overnight, and peptides
were extracted 3 times with 50% acetonitrile, 5% formic acid, dried in a speedvacuum, and stored at -20°C until sequencing analysis.

LC-MS/MS Analysis
Digests were resuspended in 20 pL Buffer A (5% Acetonitrile, 0.1%
Formic Acid, 0.005% heptafluorobutyric acid (HFBA)) and 3 - 6 pL were loaded
onto a 12-cm X 0.075 mm fused silica capillary column packed with 5 pM
diameter C-18 beads (The Nest Group, Southboro, MA) using a N2 pressure
vessel at 1100 psi. Peptides were eluted by applying a 55 minute, 0 - 80% linear
gradient of Buffer B (95% Acetonitrile, 0.1% Formic Acid, 0.005% HFBA) at a
flow rate of 130 pL/min with a pre-column flow splitter resulting in a final flow rate
of -2 0 0 nL/min directly into the source. The LCQ-DecaXP (Thermofinnigan) was
run in automatic collection mode with an instrument method composed of a
single segment and 4 data-dependent scan events with a full MS scan followed
by 3 MS/MS scans of the highest intensity ions. Normalized collision energy was
set at 30, activation Q was 0.250 with a minimum full scan signal intensity at 5 X
105 and a minimum MS2 intensity at 1 X 104. Dynamic exclusion was turned on
utilizing a three-minute repeat count of 2 with the mass width set at 1.50 Da.
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Sequence analysis was performed with Sequest™ using an indexed human
subset database of the non-redundant protein database from NCBI. Processing
of the samples through the LC-MS/MS identified the most abundant 200-300
peptides in the sample. All sequence determination was performed by Michael
Ward at the Eastern Virginia Medical School Proteomics Facility.

Transgenic adenocarcinoma murine prostate (TRAMP) model
In vitro
The TRAMP-C1P3 cells were kindly provided by Drs. Kenneth Somers
and Richard Ciavarra (134). Stably expressing HSV-TK and active site variants
TRAMP-C1P3 lines (TRAMP-TK, GK1 and GK2) were generated and
characterized for sensitivity to GCV and UCN-01. These cell lines were
generated and characterized with the assistance of Adrienne Granger and Dr.
Drake following transfection and G418 selection with a bicistronic HSV-TK/neo
Moloney Murine Leukemia Virus-derived plasmid, pLTKEN, as previously
described (23). Cells were maintained in Dulbecco’s Modified Eagle Medium 1X
high glucose with L-glutamine and without sodium pyruvate (Gibco), 5% NuSerum IV (Collaborative Biomedical Products), 5% FBS from Hyclone, 5pg/ul
insulin (Sigma), 25ug/ml penicillin-streptomycin (Gibco), and .001 pM
d ihyd roxytestostero ne.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

48
In vivo
HSV-tk variants: C57/BL6 mice were injected subcutaneously with 5X106
cells comprised of 90% parent TRAMP-C1P3 and either 10% TRAMP-TK
(wt)(n=18), 10% TRAMP-GK1 (n=18), 10% TRAMP-GK2 (n=6). After 20 days,
mice were randomized within their respective groups and half were treated with
GCV (7 or 70 mg/kg, i.p. once daily) for 5 days. Tumor volumes were monitored
by calipers starting at day 22.
For initial evaluation of UCN-01 and GCV treatments, twenty C57/BL6
mice were each injected with 5 X 106 cells comprised of 90% parent TRAMPC1P3 and 10% TRAMP-TK cells in the chest wall (ectopic model). This ratio was
used to better reflect the clinical aspects of HSV-TK/GCV therapy, and to ensure
that the injected cells would form tumors, in case G418 selection of the TRAMPTK modified their in vivo properties. Tumors were allowed to grow for 22 days,
prior to randomization into four groups of 5 mice each. Five mice each were
injected i.p. with either 70 mg/kg GCV once daily for five days (days 22-26), 2
mg/kg UCN-01 for 5 days, or a combination of both (70 mg/kg GCV and 2 mg/kg
UCN-01) for 5 days. Tissue sections from a subset of these treated mice were
saved, but have not yet been profiled for tumor infiltrating cells and cytokines to
evaluate an immune response.
This in vivo experiment was a collaborative effort including Dr. Richard
Drake and Saurabh Gupta for mouse handling and injections, and Dr. Ciavarra
overall assistance and consultation. If any animal began to show signs of pain or
distress (loss of body condition, inability to ambulate, loss of appetite, etc.) or if a
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tumor volume exceeded 10% body weight, the animal was euthanized. Data
were analyzed using a 2-way ANOVA analysis using Prism GraphPad Software
(San Diego, CA). Repeated measures analysis of variance was used to test for
significant differences among the treatment effects and indicated whether there
were significant differences (p=< 0.05). A minimum of five mice were randomly
assigned to each treatment group. All procedures were approved by the EVMS
IACUC and were in compliance with the NIH guide for the Care and Use of
Laboratory Animals.
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CHAPTER III
AIM # 1: EVALUATE THE ROLE OF THE CELL CYCLE, CELL
DEATH MECHANISMS, AND PROTEOMIC EFFECTS OF CELLS
TREATED WITH HSV-TK/GCV AND UCN-01 DRUG
COMBINATIONS

In previous studies, MTT and clonogenic survival assays showed the
combination of UCN-01 and HSV-TK/GCV had an apparent synergistic killing
effect on HSV-TK expressing colon and breast cancer cell lines (60). UCN-01
has been paired with other DNA-damaging agents including nucleoside analogs,
and a similar synergy has been observed (85, 95) and as summarized in Table 3
in the Introduction. By comparing the response of HSV-TK expressing tumor
cells to GCV and UCN-01 singly and in combination, the mechanistic basis for
how these drugs effect cell cycle and DNA damage response proteins inhibited
by UCN-01 upstream of the DNA damaging events caused by GCV was
evaluated. The mechanism of both drugs and the combination remains largely
unknown.

UCN-01 is a potent Chk1 inhibitor has this led us to our first studies

that have implicated the cell cycle proteins as the main targets for our
mechanism. Our first question was how the cell cycle is involved in the
mechanism of cell death and if that cell death involved classical apoptosis.
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Synchronization and cell cycle analysis
Previous data generated in the Drake laboratory have indicated that cdc25C
protein levels decrease after treatment of cells with UCN-01 and the combination
with GCV, and subsequently, studies of the cell cycle effects of these drugs were
pursued. To better address these effects, SW620.TK and HCT-116.TK cells
were synchronized at the Gi/S boundary using a double-thymidine block
procedure prior to UCN-01 and GCV treatments. As described in Materials and
Methods, this procedure routinely resulted in synchronization of at least 95% of
the treated cell populations. Following the second thymidine block, cells were
released into media alone, or media containing 10 pM GCV, 0.3 pM UCN-01 or
10 pM GCV/0.3 pM UCN-01. At different time points, cells were analyzed for cell
cycle progression using propidium iodide staining of DNA, BrDU labeling, or
multiple Western blot analyses.

Propidium iodide staining and flow cytometry
As presented in Figure 1, SW620.TK cells released into media alone
following double-thymidine treatment progressed through one cell cycle as a
synchronized population. By the end of 24 hrs and completion of the
synchronized cycle, the cells returned to a normal unsynchronized growth
pattern. Cells released into 10 pM GCV alone never progressed past late Sphase/early G2 phase. Cells released into 0.3 pM UCN-01 appeared to progress
normally through the cell cycle, but at a slightly altered rate relative to control
cells. There also appeared to be a greater accumulation of cells into G1
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Fig. 1. Double Thymidine Block Cell Synchronization - Flow Cytometry
Evaluation of GCV and UCN-01 Effects. SW620.TK cells were treated with 2 mM
thymidine for 16 hrs, followed by growth in fresh media for 9 hrs, then another 2
mM thymidine dose for 16 hrs (46). Cells were released into media, 10 |j M GCV,
0.3 |j M UCN-01 or 10 pM GCV/0.3 |j M UCN-01. At different time points, cells
were removed and fixed in 70% ethanol. Cell pellets were resuspended in
propidium iodide and DNA content was measured using a FACScalibur flow
cytometer (Becton Dickinson).
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following mitosis, consistent with results described in previous UCN-01 studies
(67, 135, 136).

Cells treated simultaneously with the same UCN-01 and GCV

concentrations remained largely in S-phase, but with an apparent broader
spectrum of cells in S-phase and early G2. However, like with GCV treatment
alone, no cells apparently progressed through to mitosis.

Bromodeoxvuridine Metabolic labeling coupled with flow cytometry
It is difficult to interpret rate and cell cycle accumulation versus arrest using
PI staining only; therefore, we used bromodeoxyuridine (BrDU) labeling coupled
with 7-AAD (7-aminoactinomycin D) DNA staining to track cell cycle progression.
Cells were synchronized as stated above, however they were pulsed for 2 hours
with 10pM BrDU before harvesting at each indicated time point. Our system was
unique in that the cells we were testing were already stably transfected with
HSV-tk, and BrDU is a substrate for this enzyme. In fact, a 5-bromo derivative,
5-bromovinyldeoxyuridine (BrVUrd), is one of the most potent and selective
inhibitors of HSV-1 viral replication because it is one of the best substrates
identified for HSV-tk (137). Therefore, we restricted the cells to the pulsed time
to address our cell cycle question because any long-term incubation with BrDU in
the HSV-tk expressing cell could affect cell viability and cell cycle response.
Synchronized SW620.tk cells treated with media only (control) actively took
up BrDU and were progressing into G 2 at the 6-hour time point (Figure 2), and at
the 12-hour time point, control cells had lower levels of BrDU because they had
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most of the population was in Gi (Figure 2). In contrast, GCV treated cells
appeared to already have lower incorporation of BrDU by 6 hours, indicative of
an S-phase arrest. By 12 hours GCV treated cells were still in S-phase with even
less BrDU incorporation. At 6 hours, cells began to accumulate in S-phase after
the combination of UCN-01 and GCV; however, BrDU incorporation levels
remained higher than in cells treated with GCV only. Although all levels of BrDU
incorporation were fairly low at 12 hours, it is believed that the lower levels in
control and UCN-01 are due to the population of cells in G 1, and the lower levels
in GCV and U+G are due to cells in an S-phase arrest. If the GCV treated cells
were accumulating in S-phase as opposed to arresting, a DNA profile in S-phase
with high levels of BrDU incorporation similar to the 6 hour time point of U+G
would be expected.
UCN-01 results were more difficult to interpret because by 6 hours, it
appeared that most of the population of cells were in Gi and G 2 /M phases of the
cell cycle compared to the synchronous control population in G 2 /M (Figure 2). In
order to determine if these UCN-01 treated cell were cycling more rapidly or were
having difficulty exiting G 2 , SW620 parent cells (no HSV-tk) were chosen for
tracking BrDU incorporation after pre-incubation followed by UCN-01 treatment.
Two separate but parallel experiments were conducted in the SW620 cells, one
set with a 2 hour pulse of BrDU prior to harvesting the cells and the other with a
36 hour pre-incubation that was removed when the treatment conditions were
added to the cells. In Figure 3, nearly all of the control and UCN-01 treated cells
had incorporated BrDU as expected during the 36 hour pre-incubation and were
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transiting from Gi at the 0 hr time point into G2 /M by the 12 hour time point. By
24 hours, the decrease in BrDU cells is expected as control and UCN-01 cells
divide and return to Gi. However, there appears to be a sharp decrease in Sphase cells and almost twenty percent less BrDU positive cells. Pulse data in
Figure 4 confirm these findings. By 24 hours with UCN-01, there are not as
many BrDU positive cells compared to control and a sharp decrease in cells in sphase.

Western blots of cell cycle proteins
The SW620.TK cells were synchronized, treated with UCN-01 and GCV and
then harvested at several time points. The effects of these treatments on protein
levels of cdc25C, c d k l, phospho-cdkl, Cyclin B, Cyclin A and Bcl-XLevaluated
by western blots. As shown in Figure 5, cdc25C levels varied between steady
and possibly accumulating with cell cycle phase in the control cells and in the Sphase arrested GCV treated cells, but progressively decreased dramatically after
8 hrs following UCN-01 or UCN-01/GCV treatments. A similar loss of protein in
response to UCN-01 and UCN-01/GCV after 8 hrs was observed for cyclin B
(Figure 5), and after 4 hrs for cyclin A (Figure 5). For c d k l, a phospho-tyrosine
specific antibody (for Tyr-15) and polyclonal antibody were used. In the UCN-01
treated cells, a total loss of the Tyr-15 phosphorylated form of c d kl occurred
after 8 hours (Figure 5). In the UCN-01/GCV treated cells, a persistent loss of
Tyr-15 phosphorylation occurred between 8 hrs and 31 hrs (Figure 5). Levels of
cdkl protein remained largely unchanged in all of the treatments (Figure 5).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

59

Control

GCV+UCN-01

Control

GCV+UCN-01

Cyclin A

Bcl-XL

Control

»

i

i

- 1

UCN-01

i

i

GCV

GCV+UCN-01

0

4

8

12

24

30 0

4

8

12

24

30

Fig. 5. Western Blot Determinations of cdc25C, cyclin B, cyclin A, Cdk1/cdk1P, and Bcl-xl in SW620.TK Cells Treated with GCV and UCN-01. SW620.TK
cells were double thymidine synchronized, then released into media, 10 |j M
GCV, 0.3 pM UCN-01 or 10 pM GCV/0.3 pM UCN-01. At different time points
cells were removed and processed for Western blot analysis.
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Lastly, the levels of Bcl-XL were evaluated (Figure 5). Only in the later time points
of the UCN-01/GCV combination was there a dramatic reduction present in the
levels of B cI-Xl . A similar effect on Bcl-XL levels in response to this combination
was previously reported in HCT116.tk cells (60). For GCV treatments alone, the
levels of each protein evaluated were stabilized or slightly increased (Figure 5).
Similar cell cycle responses and Western blot profiles were obtained in double
thymidine blocked HCT-116.TK, MDA-435.TK, and DU145.tk cell lines treated
with the GCV and UCN-01 combinations (data not shown).

Cell death assays
The induction of apoptosis in the SW620.TK cells following double thymidine
block and treatment with the same GCV and UCN-01 combinations was
evaluated by caspase 3-DEVDase assays and nuclear morphology staining with
DAPI. Within 6 hrs, UCN-01 and UCN-01/GCV led to activation of caspase 3,
while GCV caused a steady increase in caspase 3-DEVDase activity over
treatment time (Figure 6). The decrease in UCN-01/GCV caspase activities are
reflective of cell viabilities at the later time points. In Figure 7, DAPI-staining
indicated nuclear morphologies indicative of apoptosis, especially in the UCN01/GCV treated cells. GCV alone causes a noticeable S-phase swelling of nuclei,
indicative of S-phase arrest as previously reported (8). To comparatively assess
the effects on nuclear morphology, quantitation of relative nuclear sizes of the
cells after different treatments were determined overtim e, as presented in Figure
8. Clearly, there are pronounced differences between the nuclear sizes of cells
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Fig. 6. Caspase 3 Assays SW620.TK Cells Treated with GCV and UCN-01.
SW620.TK cells were double thymidine synchronized, then released into media, 10
pM GCV, 0.3 pM UCN-01 or 10 pM GCV/0.3 pM UCN-01. At different time points,
in triplicate, cells were removed and assayed for Caspase 3 activity using a
Clontech colorimetric kit with DEVD-pNA cleavage from protein extracts derived
from 2 X 106cells. DEVDase activities were quantitated at 405 nm.

Control

10 uM GCV

O.SpMUCNOl UCN01+GCV

DAPI

Fig. 7. DAPI-Staining of SW620.TK Cells treated with GCV and UCN01 . SW620.TK cells were plated in 8 well chamber slides (2 X 105/well),
double-thymidine blocked, and released with media for the indicated
GCV and UCN-01 combinations for 24 hrs. The cells were fixed in
methanol and stained with 1pg/ml DAPI; cells were visualized with a
Zeiss flourescent microscope on 40X magnification.
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treated with GCV that increased with treatment times, and cells treated with
UCN-01 or the combination of the two drugs.

Metabolic labeling
It has been previously described that UCN-01 treatment leads to decreased
expression of thymidylate synthase (138). Because it is also known that inhibition
of thymidylate synthase increases the effectiveness of GCV phosphorylation in
HSV-TK expressing cells due to loss of competing intracellular thymidine
nucleotides (139), the effect of UCN-01 on metabolism of [3H]GCV was evaluated
in thymidine-blocked SW620.TK cells. Following 18 hrs treatment with [3H]GCV
(1 pM) alone, or with 0.3 pM UCN-01, methanol soluble nucleotides and GCVincorporated DNA fractions were isolated and quantified for levels of [3H]GCV.
Phosphorylated [3H]GCV metabolites were separated from [3H]GCV using thin
layer chromatography plates. As shown in Figure 9, a greater than 4-fold
increase in soluble GCV-DP/TP metabolites and a 2-fold increase in GCVincorporated DNA were present in the UCN-01 treated cells. This effect of UCN01 on increasing the intracellular levels of GCV metabolites may represent the
pharmacologic basis for the contribution of GCV to the increased rate of tumor
cell killing following UCN-01 and GCV treatment combinations. W e have also
hypothesized that the combination allows GCV incorporation in the DNA to go
unrepaired due to the known inhibition of NER (Nucleotide excision repair)
proteins by UCN-01 (79) plus the damage it is causing itself.
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Fig. 8. Average nuclear size post treatment. SW620.TK cells grown in
chamber slides were double thymidine synchronized, then released into media,
10 pM GCV, 0.3 pM UCN-01 or 10 pM GCV/0.3 pM UCN-01. At different time
points, the cells were fixed in methanol and stained with 1pg/ml DAPI, and
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Fig. 9. Metabolic Labeling with [3H]Ganciclovir. SW620.TK cells were plated (5 X105/well) in
triplicate in a 6-well plate, then incubated for 18 hours in 1.5 ml of media containing 1 pCi
[3H]GCV/1 pM GCV alone (light bars), or in combination with 0.3 pM UCN-01 (dark bars).
Nucleotides were extracted with 70% methanol, and the supernatants were separated on
PEI-cellulose thin layer chromatography plates with 1M LiCI as previously described (8).
The values for GCV-monophosphate (GCV-MP) and the combined diphospate/triphosphate
levels (GCV-DP/TP) are presented. The methanol insoluble pellet was extensively washed
and quantitated as an indicator of DNA incorporation by scintillation counting (8).
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The effects of proteosome inhibition on the UCN-01 mechanism
W e hypothesized that the ability of UCN-01 to kill the cells so effectively
could be linked to its ability to target the essential mitotic proteins for
degradation. Therefore, we treated the SW620.tk cells with the proteosome
inhibitor lactacystin followed by GCV, UCN-01, and the combination. Cells were
harvested at different time points and analyzed by flow cytometry. Lactacystin by
itself appeared to “arrest” the cell in G2, and UCN-01 plus lactacystin showed
subtle signs of abrogating that arrest (Figure 10) as a small peak in Gi appeared
at 24 hours with cells treated with lactacystin and UCN-01. Interestingly, U+G
combined with lactacystin appeared to be arrested in S-phase from 4-12 hours,
but by 24 hours, the majority of the cell population appeared to be in G2. These
data are particularly difficult to interpret since initial combinations of UCN-01 with
lactacystin in our cell systems have resulted in rapid and enhanced cytoxicities,
making it difficult to interpret the role of the proteasome in the process.

Order of addition
Cell viability assays were used to determine the efficacy of changing the
order of addition with the combination of GCV and UCN-01. For these
experiments, one drug was added singly for 12 hours then the second drug was
added. GCV added first showed significantly enhanced cell killing at as low as
25nM UCN-01 added 12 hours later. This level of killing was equivalent to the
two drugs added simultaneously (Figure 11). UCN-01 added first then the
addition of GCV 12 hours later was never as toxic as the GCV first or the
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Fig. 10. Flow cytometry in Synchronized SW620.tks treated with
Lactacytstin. Following double-thymidine block, SW620.tk cells were released
into media, 10 mM GCV, 0.3 |j M UCN-01 or 10 |j M GCV/0.3 |j M UCN-01 as
before, but also in the prescence of 10 pM lactacystin. At different time points,
cell were removed and fixed in 70% ethanol. Cell pellets were resuspended in
propidium iodide and DNA content was measured using a FACScalibure flow
c y to m e te r (B e c to n D ic k in s o n )
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Fig. 11. Cell Viabilities: UCN-01 and GCV Order of Addition. UCN-01
drug doses or GCV (at 10 |jM) were added singly 12 hours apart. After 48
hours, MTT was added to determine cell viabilities. The 0 pM UCN-01 lanes
represent the GCV alone samples. The first bar series represent UCN-01
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Fig. 12. Order of addition DAPI-Staining of SW620.TK Cells treated with GCV and
UCN-01. HCT116.TK cells were plated in 8 well chamber slides (2 X 1 05/well), double
thymidine blocked, and released with media for the indicated GCV and UCN-01
combinations for 24 hrs. The cells were fixed in methanol and stained with 1pg/ml DAPI;
cells were visualized with a Zeiss flourescent microscope on 40X magnification.
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Fig. 14. Order of Addition: Western blots of mitotic proteins.
SW620.tk cells were treated with 2mM thymidine for 16 hours followed by
growth in fresh media, then another 2mM thymidine for 16 hours. Cells were
released into media, 10 pM GCV, 0.3 pM UCN-01, U+G, GCV for the first 12
hours then UCN-01, or UCN-01 for the first 12 hours then GCV. At different time
points, cells were removed and processed for western blot analysis.
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combination, and these data also coincided with DAPI staining results. The
different combinations of UCN-01+GCV consistently generated DAPI stained foci
indicative of apoptosis, as shown in Figure 12.
Double thymidine synchronized cell cycle studies revealed that cells
treated with GCV at any point had more cells in S-phase than compared to UCN01 treatment alone, and this appears to prevail in UCN-01/GCV treated cells.
(Figure 13) In Figure 14, western blots revealed that the addition of UCN-01,
whether it was first or 12 hours later, appeared to dominate the effects on
cdc25C, cyclin B, and CDK1 by promoting their disappearance.

Global proteomic approaches
SELDI-TOF MS
In 2001, our laboratory was connected to a state of the art proteomics
facility allowing access to global proteomics tools. Surface Enhanced Laser
Desorption Ionization Time of Flight (SELDI-TOF) Mass spectroscopy was one
such method, and it was pioneered in 1993 by Hutchens and Yip (140) and
commercialized by Ciphergen Biosystems. This process involves adding
samples to aluminum ProteinChips® with different chromatographic surfaces.
These chips allow for specific, selective binding of proteins in a sample to a
particular surface chemistry while washing away any non-specific interactions (as
reviewed by (141)). SELDI seemed beneficial in our quest to determine a
complex signaling pathway after treatment with GCV, UCN-01, and UCN01 +GCV; therefore, we applied this method to analyze cell lysates and nuclear
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Fig. 15. SELDI-tof Profiling of SW620.tk cells treated with UCN-01 and
GCV. SW620.tk cells (5X106) were treated with media, 10 pM GCV, 0.3 pM
UCN-01 or 10pM GCV/0.3pM UCN-01 for 24 hours. Total cell lysates were
prepared in Tris/1% TX-100 lysis bufer plus sonication. Supernatant was
applied to a strong cation surface ProteinChip from Ciphergen Biosystems. A
surface-enhanced laser desorption/ionization (SELDI) PBS-II mass reader
(Ciphergen Biosystems) was used to generate the indicated protein spectra,
mass ranges from 0-20000 daltons.
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Fig. 16. SELDI-tof MS Analysis of Nuclei from drug treated SW620.tk cells. 2
X106 cells were plated in T-75 tissue culture flasks, synchronized, and drug
treated as previously described. After 24 hours, the cells were harvested. The
nuclear fractions from the cells were separated from the cytosol and membranes,
and enriched by differential centrifugation using NE-PER reagents from Pierce.
The nuclei were diluted and loaded onto the prepared ProteinChips. (Strong
Anion Exchange (SAX) in this figure) After the chips dried, the energy adsorbing
molecule, Sinapinic Acid (SPA) was added to each spot. The coated chips were
placed in the mass spectometer. Data was collectedat a low laser energy to
obtain sharp peaks in the low mass range. The data was recorded by Ciphergen
Biosystems analysis software.
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lysates of cells treated with GCV, UCN-01, and U+G. Several attempts were
made to optimize the system, and as shown in Figures 15 and 16, Strong Anion
Exchange (SAX) chips produced excellent spectra with low background for
comparison with both cell lysates and nuclear lysates. As expected, the quality
spectra produced several drug specific peaks. However, identification of these
drug-specific peaks was not possible with SELDI methods, and remains to be
followed up on with the newer instrumentation now available in the Center for
Biomedical Proteomics.

Two-Dimensional Gel Electrophoresis (2D gels)
Another powerful tool for our proteome comparisons was two-dimensional
gel electrophoresis.

This is an attractive technology for its abilities for

comparisons of many proteins at once between samples and further identification
of spots of interest via spot extraction, trypsin digest, and MS analysis. The
sample rehydration/lysis buffer provided by BioRad was used to lyse the cells at
100,000 cells per 10Oul ratio, and then the RC/DC protein concentration
determination kit (BioRad) was used to determine protein concentration.
Optimization of this approach yielded excellent spot formation by loading 20-60
pg of protein. Figure 17 shows very distinct and well-resolved protein separation
between drug treatments. Spots of interest were identified and excised from the
gels. Prohibitin was identified in all drug treatments and was not visible in the
control gel, and peroxiredoxin (aka Natural Killer enhancing factor) was identified
in Control and GCV gels, but was not visible in the UCN-01 or U+G gels. NM23
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Fig. 17. 2D Gel electrophoresis of control and drug treated SW620.tk cells.
SW620.tk cells were plated and drug treated for 24 hours. 20pg of cell lysates were
loaded onto pH 5-8 IPG strips and focused 35000 volt hours. Strips were
subsequently run on 8-16 % gradient gels, and then the gels were silver stained.
Spots of interest: Square= Peroxiredoxin; circle= NM23; hexagon= prohibitin;
triangle= spots in the queue.
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Fig. 18: 2D Gel Electrophoresis of control and drug treated SW620.tk
nuclear lysates. Nuclear lysates were prepared as described in Materials and
Methods. 20pg of protein from the nuclear lysates were added onto pH 3-10
IPG strips and focused for 35000 volt hours. Strips were subsequently run on
8-16% gradient gels, and then gels were silver stained. Spots or areas of
interest have been marked on the gels. No protein identifications are available
yet.
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was identified in all the samples, (see Figure17 for labeled locations of these
spots)
Since many of our target proteins reside in the nucleus, we prepared
nuclear lysates of SW620.tk cells after drug treatments. It was thought that this
additional purification step prior to loading the sample onto the IPG strip would
allow for examination of the cellular compartment of interest and reduction of the
number of proteins to examine. Nuclear lysates were run on 2D gels, and the
protein spots resolved well. Currently, we do not have the identity of any
differential spots, but excised spots are in the queue for identification as indicated
on the gels in Figure 18.

Discussion
Using a combination of cell cycle analyses, western blots and apoptosis
assays in synchronized cell cultures, the single and combination effects of UCN01 and GCV on the cell cycle were evident. One of the most significant results in
respect to GCV mechanism was the profound S-phase arrest in the synchronized
cells, even in the presence of UCN-01. GCV alone led to an S-phase specific
cell cycle arrest and steady levels of all six proteins examined by Western blot.
Apoptosis of the GCV-treated cells was S-phase specific, and caspase 3
activation increased steadily from 6-31 hours. Under the conditions tested in the
synchronized SW620.TK cells, UCN-01 led to a time dependent disppearance of
cyclin B, cyclin A and cdc25C proteins, and loss of phosphorylation of Tyr15 on
Cdk-1. Caspase 3 was maximally activated within 6 hrs of UCN-01 treatment.
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UCN-01 plus GCV did not alter the cell cycle arrest in S-phase, but it did
accelerate induction of apoptosis. The S-phase specific death is similar to that
reported with gemcitabine and UCN-01 combinations (85). The UCN-01/GCV
combination caused the same effects on the cyclins and cdc25C as with UCN-01
alone, but at a slower rate. A more pronounced decrease in Bcl-XL levels was
evident within 24 hrs. The nuclear morphology of the combination treated cells
reflected that of UCN-01 treatment, in contrast to the S-phase induced swollen
nuclei morphology of GCV alone. The dose of 300 nM UCN-01 is a median one,
and we have observed empirically that the cellular effects described are
consistent in the 50-500 nM ranges, but diminish below 30 nM doses (data not
shown).
The key observation in the initial experiments was the drug induced
decrease in cdc25C protein levels (Figure 5). Before determining that the GCV
and UCN-01 combinations in synchronized cells was an S-phase specific
response, we had hypothesized that UCN-01 inhibition of Chk1, and therefore
continued activation of cdc25C, would result in activated cdkl/cyclinB
complexes, abrogation of a G2-block, and entrance of the cell into the mitotic
phase as has been reported for UCN-01 in combination with camptothecin (88),
cisplatin (86), or mitomycin C (89).
Our lab has shown previously that the absence of cdc25C after 24 hours
of UCN-01 treatments contrasted that of the effect of 100 nM taxol. As we had
previously reported, taxol and GCV combinations in the SW620.TK cells leads to
non-additive interactions and increased cell viability in the time frame of the
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experiments(60). It is known that one of the primary effects of taxol is to cause a
G 2/M phase arrest due to stabilization of the microtubule spindle fibers (142,
143), although this effect is variable depending on the taxol concentrations
utilized. High doses of taxol (0.2-30 pM) are required to induce maximal
microtubule effects and induction of apoptosis, while low range doses (1-100 nM)
can have multiple cell cycle and apoptotic effects depending on cell tumor type
and dose duration (142). These results are consistent with the S-phase arrest
caused by GCV, which likely prevented the arrested cells from interacting with
taxol during its most effective phase of the cell cycle, G2/M.
Because many studies have shown that UCN-01 plus a DNA damaging
agent results in better cell killing than either drug alone (64, 67), the UCN-01 plus
GCV data further reinforce the mechanistic observations that GCV incorporation
into DNA is a primary pharmacological activator of cellular responses. This effect
is consistent with the reported inhibitory functions of UCN-01: the AKT survival
pathway (78), DNA excision repair (79), and Chk1 (73). Other effects that we
have identified indicative of the UCN-01 and GCV combinations besides our
original observations of increased apoptosis (60) included a heightened
degradation of B c I-X l (Figure 5), acceleration of the GCV-induced S-phase
apoptotic cell death (Figure 2), and increased incorporation of GCV into DNA in
the presence of UCN-01 (Figure 8). The combination of GCV and UCN-01
caused enough of a DNA damage response that there is no mitotic progression,
apparently due to the UCN-01 induced degradation of regulatory proteins like
cyclin B and cdc25C. This ultimately led to increased rates of apoptosis, as
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indicated by the DAPI staining and caspase activity assays (Figures 6-8).
Furthermore, UCN-01 promotes increased incorporation of GCV into the DNA
(Figure 9), probably by two mechanisms. Because GCV alone leads to an Sphase arrest, the addition of UCN-01 may inhibit part of those repair mechanisms
or checkpoints induced by GCV, and thus allow further incorporation of GCV-TP
into nascent DNA strands. Also, since UCN-01 has been reported to suppress
the transcription of thymidylate synthase (138), the result is less intracellular
thymidine nucleotides present that could compete with GCV for phosphorylation
by HSV-TK. It has been well documented in combination therapies of HSVTK/GCV with cytidine deaminase/5FC (139, 144), or hydroxyurea (58), GCV
metabolism is enhanced when thymidine nucleotide pools are depleted. The
multiple inhibitory functions of UCN-01 thus contribute to this increased GCV
incorporation, thus contributing to the acceleration of apoptotic cell death seen
with the GCV and UCN-01 treatments.
From the perspective that GCV treatment leads to DNA damage, and that
UCN-01 treatment leads to the potential degradation of cdc25C, what then is the
mechanism by which cdc25C is being targeted for degradation? For another
cdc25 family member, degradation of cdc25A by the ubiquitin-proteasome
pathway is well documented (145-149). However, reports of similar degradations
of cdc25C in response to DNA damage or drug treatments are less well defined,
and only recently being described (150-153).

In one study (153), arsenite

treatment was shown to induce cdc25C degradation through the ubiquitinproteasome pathway. There is also evidence linking cdc25C degradation to p53
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status of the cell. HCT116 p53 +/+ cells infected with adeno-associated virus
(AAV) showed degradation of cdc25C following a G 2 cell cycle arrest response.
In contrast, AAV induced apoptosis in HCT116 p53 -/- cells, but cdc25C levels
remained steady (152). However, we have not seen major differences in the
levels of cdc25C degradation following UCN-01 treatments in relation to p53
status of the HSV-TK cell lines tested, including HCT116 (p53+/+) and SW620
(p53 -/-). Clearly, more studies evaluating the mechanism of cdc25C degradation
and its regulation in response to UCN-01 and UCN-01/GCV treatments are
warranted. For example, how the degradation of cdc25C is linked to other DNA
damage response regulators like Chk1 and Chk2, both known to be inhibited by
UCN-01 and use cdc25C as substrates, remains to be delineated.
At the time when the SELDI-TOF spectra were obtained, algorithms used
to classify and determine “peaks” were still being developed and had only really
been successful on serum analysis using a “quality control" or pool of sera to
provide a signature spectra for experiment to experiment comparisons. Since
completing our SELDI experiments, equipment for sample preparation has
evolved quickly. ProteinsChips® and samples can now be completely prepared
in an automated fashion with a robot, and this boosts reproducibility allowing us
to derive conclusions from experiment to experiment more confidently.
Interestingly, once peaks of interest have been identified from the spectra, the
chemistries of the chip surface can be used for subsequent purification and
identification of the peaks (as reviewed by (141)).
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In the 2D gel experiments, making comparisons completely by eye proved
extremely daunting, however, computer software is now available to assist in
identification of proteins of interest. We have obtained BioRad imaging software
called PD Quest set to help analyze the gels. Since gel to gel differences,
sample preparation and sample origin can all cause differential spots, it will be
imperative to set up multiple replicates for each condition so the software have
multiple gels of each condition to set up representative templates of each gel.
Comprehensive proteomic studies using 2D gel technology have been suggested
in Chapter VI: Conclusions.
Use of the two-drug combination has also identified a putative molecular
pathway whereby the DNA-damage resulting from GCV incorporation translates
into arrest of cells in S-phase. Further delineation of the components of this
pathway and specific target proteins involved in the surveillance, signaling, and
repair of DNA damage are the focus of Chapter IV of this dissertation.
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CHAPTER IV
AIM #2: DNA DAMAGE AND REPAIR: IMPLICATIONS FOR
MECHANISM AND EFFICACY OF HSV-TK/GCV AND UCN-01
TREATMENT SCHEMES

The main focus of investigation into the mechanism of UCN-01 by our lab
and others has been related to the cell cycle, yet newer studies have shown that
the inhibitory effect of UCN-01 is not always related to cycle progression. In
section A, we revealed that UCN-01 can abrogate survival in GCV treated TK
expressing cells that are arrested in S-phase without cell cycle progression. This
still had not answered the questions about how UCN-01 was acting used singly
and with HSV-tk/GCV treatments. Based on our observations, we began to
consider the different actions of UCN-01 as an agent that disrupts the equilibrium
between activation and inhibition of DNA repair processes. W e began our
studies with a global approaches using powerful tools such as SELDI-TOF mass
spectroscopy and confocal microscopy, however, our concluding studies focused
specifically on a potentially new DNA damage mechanism of UCN-01.

Evaluation of abrogation of G2/M arrest
Since caffeine is a known Chk1, ATM/ATR inhibitor it was tested in
combination with GCV to compare with the enhanced killing when cells are
treated with UCN-01. Figure 19 shows GCV plus caffeine did not produce
enhanced cell killing. Furthermore, we did establish that UCN-01 was able to
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Fig. 19. Cell Viabilities of Cells after Caffeine and GCV treatment. SW620.tk
cells were treated with increasing concentrations of caffeine only or plus 10pM
GCV. MTT was added 48 hours later to determine cell viability.
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Fig. 20. Cell cycle analysis of SW620.tk cells treated with radiation and
UCN-01. Cells were synchronized and treated with media only, 4 or 12 Gy
radiation alone or combined with 0.3|j M UCN-01. Cells were harvested at the
indicated time points and resuspended in 70% ethanol.
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abrogate G 2 /M arrest in SW620.tk cells induced after irradiated the cells with 4 or
12 Gy radiation as shown in Figure 20 revealing that the signaling cascade
functions to arrest cells after radiation, and after UCN-01 is added, that arrest is
abolished. Our system can function in the classical definition of UCN-01 to
abrogate G2/M arrest, but our findings with GCV and UCN-01 treatments still
coincide with the S-phase specific cell death when combining Gemcitabine and
UCN-01 (85). These findings prompted our laboratory to seek global proteomics
changes in order to identify new leads for understanding the mechanisms behind
UCN-01 and GCV treatments.

DNA damage signaling
Immunocvtochemistrv
Since DNA damage surveillance proteins have been shown to form foci
and punctate spots upon DNA damage (115, 120),we have screened many DNA
damage response proteins using immunofluorescence as summarized in Table
5. The most distinct drug dependent localization or pattern shifts were observed
with 53BP1 and Chk1/Chk1-P (Figure 21). The immunofluorescence results of
53BP1, Chk1-P, following UCN-01 treatment is consistent with a DNA damage
response (Figure 21A and 21D) and levels of Chk1 did not change (Figure 21C);
however, it is unknown if UCN-01 is directly responsible for this damage.

The

phosphorylation of Chk1 via ATM/ATR would be expected after DNA damage, as
seen following UCN-01 treatment (compare Figure 21C and 21D). The absence
of the Chk1-P signal in the U+G treated cells could be due to the time point
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Table 5 Confocal Microscopy of proteins involved in a DNA damage response
Protein

Hours
treated/unsynchronized or
synchronized
24/unsynch
12/Synch

Differences
between drug
treatments
Yes

Description or
hallmarks

BRCA-P

12/synch

Subtle

UCN-01,
nuclear punctate

BRCA

12/synch

No

Nuclear

Chk1-P

12/synch

Yes

GCV and UCN01 bright
nuclear staining

Chk1

12/synch

No

Nuclear

Chk2

12/synch

Subtle

Follows nuclear
organization
changes;
muliple round
bodies in U+G

Chk2-P

12/synch

No

No detection at
all; no detection
in westerns

Cdc25C

12/synch
24/synch

No

Cytosolic

Cdc25A

12/synch

Subtle

Nuclear
disorganization
in UCN-01 and
U+G

53BP1

Cell Line
HT-29
MCF-7
CSC-1
NCM460

UCN-01,
nuclear and very
punctate

Table 6 Summary o f Cell lines used fo r PFGE
Description
p53 status
Colon Cancer
Breast Cancer
Normal colon
Normal colon

Mutant
Wild Type
Wild type
Wild type

Mismatch
repair status
Proficient
Proficient
Proficient
Proficient
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A.

b.

53BP1 24 hrs Unsynchronized

Control

UCN-01

Control

U+G

Chk1 after 12 hours

Control

UCN-01

53BP1 30 hours Synchronized

GCV

U+G

UCN-01

U+G

Chk1-P after 12 hours

Control

UCN-01

GCV

U+G

Fig. 21. Confocal Microscopy of 53BP1, Chk1, and Chk1-P in
Treated SW620.tk cells. 80,000 cells were seeded onto each well of
a 2-well Permanox slide. These cells were double thymidine blocked
then released in to media, 10pm GCV, 0.3 pM UCN-01, or 10pM
GCV/0.3 pM UCN-01 for 12 hours. The 24- hour panel was not
synchronized, just released into treatments. Cells were fixed and
permeabolized with 2% paraformaldehyde and 0.5% triton X-100 and
incubated with the indicated primary antibody. A) and B) 53BP1 was
from Bethyl Laboratories, C) Chk1 was from Santa Cruz and D) ChkP was from Cell Signalling Technologies. The secondary antibody
was an anti-rabbit IgG conjugated to AlexaFluor 488nm (Molecular
Probes) Images were captured using a Zeiss Confocal Microscope.
All images are maximum projections of a z series.
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analyzed. This phosphorylation could have already occurred, consistent with the
increased apoptotic responses from this drug combination, or this drug
combination could circumvent Chk1 completely.

Determination of DNA Double Strand Break Formation
vH2AX westerns
Next, phosphorylation of histone H2AX as a marker of double stranded
DNA breaks was evaluated to examine whether UCN-01 causes damage to the
DNA itself. Up to this point, we had only seen several components of the DNA
damage signaling activated, and therefore we decided to look specifically for the
kind of DNA damage that was occurring. Western blots for the phosphorylated
form of histone H2AX, yH2AX, showed induction of the phosphorylation after 30
hours of GCV treatment, 8 hours for UCN-01 and 8 hours for U+G. (Figure 22)
For reference, one DSB induces the phosphorylation of 0.03% of the total cellular
H2AX, which corresponds to 2 Mbp of chromatin (154).

Pulsed Field Gel Electrophoresis for the detection of DSBs
In light of 53BP1 immunofluorescence and yH2AX western blots, we
pursued a method to detect double strand breaks after UCN-01 treatment in TK
expressing cells. W e employed the method of pulsed field gel electrophoresis
under the supervision of Dr. Richard Britten, Ph.D. at Eastern Virginia Medical
School Department of Radiation Oncology.

Mega base pair length (Mbp) DNA

fragments can be separated by size by using pulsed electric fields with
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Fig. 22. Western Blot Determinations of yH2AX levels in SW620.tk Cells
Treated with GCV and UCN-01. SW620.tk cells were double thymidine
synchronized, then released into media, 10uM GCV, 0.3 |j M UCN-01, or
10|j M GCV/0.3|j M UCN-01, or 10 |j M GCV/0.3 |j M UCN-01. At different time
points, cells were removed and processed for Western Blot analysis. AntiyH2AX antibody was obtained from Trevigen.
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periodically changing direction. By changing pulse duration, field strength or
even agarose concentration, the PFGE protocol can be optimized for separation
of different sized fragments (155). Only DNA fragments smaller than 10 mbp can
be investigated by PFGE and many breaks have to occur per cell (113).
Unsynchronized SW620.tk cells were drug treated with 10pM GCV, 0.3pM
UCN-01, and U+G for 8 and 24 hours, and were harvested and immediately
prepared into agarose plugs. The placement of whole cells into the agarose was
to ensure that there would not be any shearing of the DNA prior to PFGE.

Initial

experiments with drug treated SW620.tk cells showed subtle DNA elution out of
SW620.tk cells treated with UCN-01 and U+G (data not shown), indicative of
double strand breaks. We then also tested several other cell lines to determine if
elution would be detectable in other cell lines tested with UCN-01. Those cells
and their descriptions are summarized in Table 6. In all cell lines tested,
compared to control, UCN-01 induced significant double strand breaks as
detectable by PFGE (Figure 23).
Since HT29.tk cells revealed increased elution after UCN-01 treatment
compared to SW620.tk cells, they were used to further evaluate DSB formation
after UCN-01 and GCV treatments. Unsynchronized FIT29.tk cells were treated
with media, GCV, UCN-01, and U+G for 8 hours and 24 hours prior to harvesting
the cells for PFGE. There were no easily detectable DSBs by 8 hours in control
and GCV treated cells; however, there was faint elution out of the UCN-01 and
U+G plugs (Figure 24). By 24 hours, significant elution was visible in UCN-01
and U+G treatment lanes (Figure 24).
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HT-29.tk

NCM 460

CSC-1

MCF7-tk

Ctrl UCN-01 Ctrl UCN-01 Ctrl UCN-01 Ctrl UCN-C1

Fig. 23. Pulsed Field Gel Electrophoresis of Multiple Cell lines
treated with UCN-01. Cell lines were plated in 100mm2 plates and
treated with 0.3 pM UCN-01 for 24hours. Cells were harvested and
processed into plugs. Plugs were run on PFGE for 24 hours using the
electrophoresis conditions described in Materials and Methods.

8 hours treatment

24 hours Treatment

Fig. 24. Pulsed Field Gel Electrophoresis of HT29.tk cells treated with
GCV, UCN-01, and the combination. Unsynchronized HT29.tk cells were
treated with 10 pM GCV, 0.3 pM UCN-01, and U+G for either 8 or 24 hours
prior to plug formation. PFGE was run for 24 hours prior to imaging with
ethidium bromide.
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Mechanism of Double Strand Break Induction by UCN-01
Inhibition of endogenous double strand breaks
Although the previous data indicates that the addition of UCN-01 can
cause double strand breaks in most cell lines tested, the origin of these double
strand breaks still had not been determined. W e next asked the following
question: Does UCN-01 inhibit the repair of endogenous double strand breaks?
A newly designed and tested DNA-Pk selective inhibitor NU7026 (2(morpholin-4-yl)-benzo[h]chromen-4-one) from Calbiochem was chosen
because it has 60-fold greater potency against DNA-Pk compared with
Phosphoinositol 3-Kinase(PI3K) and is inactive against both ATM and ATR (156).
We hypothesized that if UCN-01 was causing double strand breaks by inhibiting
the main repair pathway for endogenous double strand breaks, then we would
detect this on PFGE, and the levels of elution would be comparable to UCN-01
elution.
Figure 25 reveals that endogenous levels of double strand breaks (those
after NU7026 treatment) do not compare in size or intensity to those of UCN-01
induction; however, the combination of UCN-01 and NU7026 suggests that UCN01 could be co-dependent on active DNA-Pk for DNA signaling and further
damage because it appears that the elution is less intense. The breaks however
appear to the same size as indicated by the arrow in Figure 25. However, clonal
survival assays did not suggest that active DNA-PK was required for UCN-01
toxicity because the cells were not significantly rescued with the UCN-01 and
NU7026 combination compared to UCN-01 alone (Figure 26). A lower dose of
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Fig. 25. Pulse Field Gel Electrophoresis of HT29.tk cells
treated with media, NU7026, UCN-01, U+N, or MX+UCN01. HT29.tk cells were treated for 24 hours with media,
250nM UCN-01, 15pM NU7026, 6mM Methoxyamine or the
indicated combination. Cells were processed into agarose
plugs, and plugs were were run in PFGE for 30 hours and
stained with EtBr.
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Fig. 26. Clonal Survival Assay of HT29.tk cells treated with
methoxyamine, NU7026, and UCN-01. 2000 cells were plated per
well in a 24 well plate. The next day 15 pM NU7026, 37nM UCN-01,
6mM Methoxyamine or the combination with UCN-01 were added,
and colonies were stained and counted 6 days later. Data are
representative of three separate experiments with each condition
performed in triplicate.
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UCN-01 (37nm) was used in the clonal survival assays because higher
concentrations were too toxic for any colonies to form. In order to determine if
there was any synergy or antagonistic effects with UCN-01, the colony numbers
had to be high enough to detect these types of interactions with NU7026 and
methoxyamine.

Inhibition of Base Excision Repair
Another possible explanation of double strand break induction after UCN01

treatment is unrelated to the inhibition of endogenous double strand breaks.

We developed a more interesting but complex theory involving base excision
repair (BER). W e asked the following question: Does UCN-01 inhibit base
excision repair (BER) therefore causing double strand breaks? In Figure 25, the
BER inhibitor methoxyamine alone did not generate detectable DSBs compared
to UCN-01, but the combination of MX and UCN-01 revealed a key effect: UCN01

treated cells resulted in similar migration no matter what treatment, as long as

UCN-01 was present. In MX + UCN-01 treatments, most of the intermediate
sizes of double strand breaks were gone, and only one size appeared to migrate.

DNA Single strand breaks: Alkaline elution of agarose plugs
W e also wanted to look for DNA single strand breaks after our drug
treatments, and we adapted an alkaline method for our cells already in agarose
plugs. To our knowledge, alkaline elution has never been performed in a PFGE
system. Single strand breaks have alkaline labile sites that convert to double
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Alkaline Elution
Fig. 27. Alkaline elution Pulse Field Gel Electrophoresis of
HT29.tk cells treated with media, NU7026, UCN-01, U+N, or
MX+UCN-01. HT29.tk cells were treated for 24 hours with
media, 250 nM UCN-01, 15pM NU7026, 6 mM Methoxyamine
or the indicated combination. Cells were processed into
agarose plugs, and plugs were were run in PFGE for 30 hours
and stained with EtBr. Alkaline elution was performed by
incubating the plugs in alkaline buffer for 2 hours prior to
electrophoresis in a 0.5% alkaline buffer gel in 0.5X TBE buffer.
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strand breaks after alkaline exposure. Plugs were incubated in alkaline buffer for
2 hours prior to loading into an alkaline agarose gel. PFGE was then performed
under standard conditions as outlined in Materials and Methods in Chapter II.
Figure 27 shows no elution or single strand breaks in either control, NU7026, or
MX treated cells. Inhibition of BER did not reveal single strand breaks from cells,
but our data suggests that all cells treated with UCN-01 generated single strand
breaks. We believe that this data suggests that UCN-01 is not inhibiting repair of
DNA single strand or double strand breaks and the damage it is causing is due to
its specific interaction with the DNA itself.

Discussion
Confocal microscopy was a successful approach for evaluation of many
proteins involved in the DNA damage signaling pathways induced after drug
treatments. As we titrate drug concentrations and test multiple cell lines, we will
investigate H2AX and 53BP1 foci formation as a measure of DSB induction. This
will be compared to PFGE results of the same cells and treatments. The data
showing the phosphorylation of FI2AX within

8

hours of treatment with UCN-01

are important because UCN-01 as a single agent has never been reported to be
capable of inducing DNA double strand breaks. Furthermore, phosphorylation of
H2AX appears to play a critical role in the recruitment of repair or damage
signaling sites of DNA damage (120, 125, 157-159). Therefore, detection of this
phosphorylation fits well with our immunofluorescent data shown foci formation
with 53BP1. The indication of double stranded breaks at 30 hours of GCV
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treatment is more consistent with an observed apoptotic response to GCV (23,
60). The shorter time frame for UCN-01 could also be related to an apoptotic
response; however, it could equally be possible that this is a result of UCN-01
induced double strand breaks.
We considered using cells lines deficient in DNA-PK such as the
glioblastoma cell line M 059J, however it has been shown that they also contain
reduced levels of ATM compared to M 059K cells that have DNA-Pk (160).

The

advantage to using these selective chemical inhibitors is that they can be used in
our HSV-Thymidine Kinase stably transfected cell lines because future studies
will include the complete characterization of these inhibitors combined with GCV
treatment. Inhibition of endogenous DSB repair by treatment with NU7026 did
not produce similar PFGE results to UCN-01 treated cells. However, we are
interested in future experiements with this combination, because order of addition
may change the levels of DSBs since UCN-01 could be causing replication stress
itself, therefore adding a DSB repair inhibitor after UCN-01 would seal the fate of
the cell.
Base excision repair employs DNA lesion-specific glycosylases to
recognize and bind to the damaged sites, and remove the base. After removal of
the problem (methylated) base by a purine glycosylase, which creates the abasic
or apurinic-apyrimidinic (AP) site, the phosphodiester bond is immediately
hydroylzed by AP endonuclease (APE), initiating the repair of the AP site (104,
161). Methoxyamine specifically binds to the AP site and reduces the APE
cleavage of the backbone by more than 300-fold compared with the cleavage of
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normal AP sites (162). W e hypothesize that UCN-01 causes damage directly to
the DNA in a systematic manner, and these aberrations could be normally
repaired by BER. Fragments of different sizes elute after UCN-01 treatment, and
no smaller fragments result because BER is successful at repairing some of the
lesions. With BER inhibited, UCN-01’s systematic adduct/breakage is apparent.
The nature of this interaction with the DNA has never before been documented,
and will be need to be further studied as discussed in Chapter VI. In addition,
concentrations should be tested for their impact on elution of DNA from treated
cells, and addition of MX and NU could be altered to zero in on the signaling
mechanism for repair of UCN-01 induced lesions.
We are also intrigued in the sub-additive cell killing seen with the
combination of MX and UCN-01. Methoxyamine has been shown to significantly
enhance the antitumor effects of the methylating agent temozolomide (TMZ) in
both MMR proficient and MMR deficient human colon cancer xenografts (163).
Interestingly, Tominic e ta l. obtained data using MX indicating that protection of
HSV-tk transfected CHO cells treated with GCV was provided by DNA
polymerase beta dependent single nucleotide and long patch BER (33).
Overcoming this protection with MX is something we will pursue in multiple TK
expressing cells lines in combination with UCN-01 and GCV.
W e had mentioned that HT29.tk cells were selected for pulsed field DNA
elution studies because we were able to detect greater amounts of elution
compared to SW620 cells. As we have been investigating the DNA damage
repair inhibitory compounds by MTT and clonal survival assays, an interesting
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theme had emerged. The HT29s appear to be more sensitive to UCN-01,
correlating to higher amount of DNA eluting on the PFGE. This has been
documented before when Canman et al. report showed that increased sensitivity
to flurodeoxyuridine correlated with HT29 elution on PFGE compared to SW620
cells(164). Further studies will need to be done comparing the more sensitive
HT29 cells to less sensitive cell lines like SW620.
In summary, it is very possible that the therapeutic utility of UCN-01
comes from its effects on several targets as opposed to just one. There is
mounting evidence that UCN-01 may be interacting with the DNA, but its
existence and precise contributions of this binding to the overall cellular
cytotoxicity remain to be fully explored.
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CHAPTER V
AIM #3:
IN VITRO AND IN VIVO EVALUATION OF HSV-TK VARIANTS AND
EFFICACY OF GCV AND UCN-01 IN VIVO

Another way to improve the overall efficacy of the HSV-tk/GCV system
would be to utilize HSV-tks that were more specific for phosphorylation of GCV
relative to thymidine, thus replacing the multi-substrate functions of HSV-tk. The
study of these GCV-kinases (GK) fits well within our overall aim to improve HSVtk/GCV gene therapy using several interrelated approaches. Several metabolic
mutants were created in our laboratory using advanced modeling programs and
characterized for GCV metabolism (52) and several interesting candidates
emerged to test those effects in vitro and in vivo: GK1, GK2, and GK3.

In that

study, Mercer et al. described the kinetic properties of several site-specific
mutants of HSV-tk (52). A summary of those properties is provided in Table 7.
A previous study by Drake et al. had already established differential GCVmediated cell killing by mutants of HSV-tk (23), and those studies confirmed the
findings by several others that GCV treatment of HSV-tk expressing cells could
induce S and G2/M phase cell cycle arrests in HSV-tk expressing glioma and
melanoma cell lines (19, 21, 34, 165).
Chapter V reveals the outcome of the variants characterized in a similar
manner to wild type TK as described in Chapter III and their efficacy in vivo. We
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Table 7 Enzymatic Characteristics o f HSV-tk
Ganciclovir
Thymidine
Thymidine
HSV-tk
Km (pM)
Km (pM)
Kcat/Km
6.7X10 4
69
Wild type
0.9
40
1.1X10 3
Q7530 (GK1)
53
71
N7530 (GK2)
90
18
ND
ND
ND
N30-3 (GK3)

Table

8

IC 5 0 for GCV treatment in multiple cell ines using M TT assay
Cell Line
IC 50
DU145-tk
0 .1
TRAMP-tk (wt)
0.3
TRAMP-GK1
0.3
TRAMP-GK2
10
TRAMP-GK3
N.D.
HCT116-tk (wt)
0 .1

WT
GK1
GK2

Table 9 Summary o f GCV
GCV
% BrDU
metabolism
incorp.after
GCV
High
Lower
High
Lower
Low
Lower

GK3

Very low

Cell
line

variants
Ganciclovir
Kcat/Km
6 . 8 X 10a
3.2X10 2
84
ND

Same as
control

effects in HCT116 tk variants
Caspase-- Number of Animal
3 activity
Apoptotic
Model
cells
results
High
Medium
Apoptotic
High
High
Apoptotic
Low
High
Apoptotic
and
Necrotic
Very low
Very low
Not
determined
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concluded our studies looking at wild type TK in combination with UCN-01 and
GCV in the TRAMP tumor model.

Flow cytometric analysis of HSV-tk variants treated with GCV
Propidium Iodide Staining
As shown in Figure 28, double thymidine treated synchronized, untreated
HSV-tk expressing wild type HCT-116 cells, proceeded through a full
synchronous cycle with the majority of the cells returning to G1 within 12-24
hours. Following the addition of 10 pM GCV, these wild type TK expressing cells
accumulated in S-phase from 4-8 hours, then slowly progressed to the S/G 2
boundary at 12 hours. In contrast, the GK1 expressing cells immediately
arrested in S-phase following GCV addition, and did not progress with time. GK2
expressing cells treated with GCV did not accumulate in S-phase, but in G 1 and
G2, while GK3 cells appeared to pause in S-phase but returned to cycling as
normally as the untreated controls. These cell cycle results prompted us to test
BrDU labeling in these variants after treatment with GCV.

Bromodeoxvuridine Metabolic Labeling
As stated in Chapter III, BrDU labeling was used with the caveat that
BrDU is a substrate for HSV-tk; therefore, the cells were only pulsed for 2 hours
during the evaluation of the HSV-TK/GK variant and GCV treatment. Figures 29
and 30 show densitometry plots of BrDU and 7-AAD. The percent of cells that
were positive for BrDU is shown in the upper right corner of each graph, and this
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Fig. 28. Double Thymidine Block Cell Synchronization and Flow Cytometry of
GCV treated HSV-1 TK and GK expressing cells. HSV-1 TK, GK1, GK2 and GK3
expressing cells were synchronized by double thymidine treatment, and released
into fresh media alone or containing 10 pM GCV for 4-48 hours as described in
Materials and Methods. At the indicated times, cells were fixed in 70% ethanol,
stained with propidium iodide and analyzed by flow cytometry on a FACSCalibur
instrument (Becton Dickinson, Mountain View, CA) as previously described (7).
Presented are representative flow profiles of each time point for the GCV treated
samples.
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Fig. 29. 2 hour pulse labeling with 10 pM BrDU of Wttk and Q7530.tk
expressing cells treated with media or 10 pM GCV. HSV-tk expressing cells
(150,000) were plated in 60mm2 dishes. Cells were pulsed 2 hours prior to the
2, 12, 24, or 36 hour time points before getting harvested for flow after drug
treatment at the indicated time points. FI1= BrDU and FI3=7-AAD. The percent
of BrDU positive cells is indicated in the upper right corner.
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HSVtk variants treated with media or 10 fiM GCV. HSV-tk expressing cells
(150,000) were plated in 60mm2 dishes. Cells were pulsed 2 hours prior to the
2, 12, 24, or 36 hour time points before getting harvested for flow after drug
treatment at the indicated time points. FI1= BrDU and FI3=7-AAD. The percent
of BrDU positive cells is indicated in the upper right corner.
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Fig. 31. Summary of BrDU incorporation in untreated and 10pM GCV
treated HSV-tk variant cell lines. Percent BrDU incorporation is represented
graphically from Figures 29-30 for comparison.
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incorporation is also summarized in the line graphs in Figure 31. Wild-type TK,
GK1, and GK2 expressing cells treated with GCV had decreased levels of BrDU
incorporation compared with control. In contrast for the GK3 expressing cells,
levels of BrDU incorporation remained very similar in control and GCV treated
cells. This correlates well with what we described in Figure 28 with the cell cycle
analysis, and the decrease in BrDU uptake in GCV treated W T and GK1 cells
indicates an S-phase arrest, as opposed to accumulation in S-phase.

3[H]GCV Metabolic labeling
It is thought that higher levels of GCV metabolism and incorporation
correlate positively to apoptosis after GCV treatment (166), therefore the
metabolism of GCV was compared across the HSV-tk variants. As shown in
Figure 32, W T and GK1 expressing cells both had high levels of GCV phosphate
forms correlating with increased DNA incorporation. The GK2 and GK3
expressing cells had significantly reduced levels of GCV metabolites and
incorporation into the DNA, but GK2 expressing cells still higher metabolism than
GK3 expressing cells. Furthermore, cytotoxicity assays revealed that killing of
cells expressing HSV-TK and variants after GCV treatment (52) also correlates
with the levels of GCV incorporation shown in Figure 32.
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Fig. 32. [3H]GCV Metabolic Labeling of HSV-1 TK and GK expressing
HCT-116 cell lines. HSV-1 TK, GK1, GK2, and GK3 expressing HCT116 cells were incubated for 18 hours with 1 p.M [3H]GCV (in triplicate).
[3H]GCV metabolites were extracted with 70% methanol, and further
separated on PEI-cellulose thin layer chromatography plates with 1M LiCI
as described in Materials and Methods. Values from the GCV mono-, diand triphosphate metabolites were pooled (dark bars). The methanol
insoluble pellet was extensively washed, resuspended and quantitated by
scintillation counting, and used as an indicator of DNA incorporation (gray
bars).
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Characterization of Cell Death after GCV treatment
DAPI staining and Measurement of Caspase Activity
W T and GK2 expressing cells had the most classical indicators of
apoptosis as revealed by DAPI staining and caspase-like activity. Both variants
had more than double the caspase like activity compared to GK2 and GK3
expressing cells (Figure 35). In Figure 33, DAPI staining revealed the relative
levels of swelling that we have seen as hallmarks of GCV treatment. Figure 34
summarizes the average nuclear size of the nuclei presented in Figure 33.
Nuclei from GK3 expressing cells were the most similar to the FICT-116 parent
cell line. The same nuclei sizes at 10 pM GCV were detected in WT, GK1, and
GK2 expressing cells; however, the nuclear size in the GK2 cells was smaller at
the 1 pM GCV dose.

ApopTaq™ (Intergen) Kit for apoptosis detection
DNA fragmentation induced by apoptosis can be measured by enzymatic
labeling of the free 3’-OFI termini with modified nucleotides. The ApopTag™
method allows medium throughput analysis of many samples providing
fluorescent or colorimetric data for quantitation. The nucleotides contained in the
reaction buffer are enzymatically added to the DNA by terminal deoxynucleotidyl
transferase (TdT). TdT catalyzes a template-independent addition of nucleotide
triphosphates to the 3’-OH ends of double stranded or single stranded DNA. The
incorporated nucleotides form an oligomer composed of digoxigenin nucleotide
and unlabeled nucleotide in a random sequence. The bound anti-dioxigenin
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Fig. 33. DAPI staining of GCV treated HSV-1 TK and GK expressing cells.
Parental and HSV1 TK, GK1, GK2 and GK3 expressing HCT-116 cells were
plated in 8-well chamber slides and treated with GCV (0, 0.1, 1, 10 pM) in triplicate
for 72 hours. Cells were stained with 1 pg/ml DAPI in 100% methanol at 37°C for
10 minutes (Drake 1999 ref). The cells were visualized with a Zeiss fluorescent
microscope with a DAPI (460 nm) specific filter at a magnification of 40X.
Representative fields of DAPI-stained nuclei from parental HCT-116 (+ 10 pM
GCV), HSV-1 TK (+ 1 pM GCV), GK1 (+ 1 pM GCV), GK2 (+ 1 pM GCV) and GK3
(+10 jaM GCV) cells are shown.
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Fig. 34. Average Nuclear Size of HSV-tk variants treated with GCV. The
areas of at least 10 stained nuclei were determined using Metamorph
imaging software and plotted versus GCV dose: HSV-1 TK (diamond), GK1
(small square) and GK2 (triangle); for HCT-116 (large circle) and GK3
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Fig. 35. Caspase 3 Assays HCT116 and HCT116-tk variants Treated
with GCV. Cells were double thymidine synchronized, then released into
media, 10 mM GCV. In triplicate, cells were removed and assayed for
Caspase 3 activity using a Clontech colorimetric kit with DEVD-pNA
cleavage from protein extracts derived from 2X10® cells. DEVDase
activities were quantitated at 405 nm.
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Fig. 36. Measurement of DNA fragmentation in HSV-TK variants treated
with GCV. HSV-tk expressing cells were seeded on coverslips and
treated with 10 pM GCV. ApopTag kit was used for DNA fragmentation
detection. Arrows indicate examples of positively stained cells which are
very dark in contrast to the negative cells.
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peroxidase antibody conjugate enzymatically generates a permanent, intense,
localized staining from chromogenic substrates providing sensitive detection in
immunocytochemistry. Cells were prepared as described in Materials and
Methods, and the average number of apoptotic cells per field at 25X
magnification were visualized and counted with a light microscope. Number of
apoptotic cells GCV/Ctrl treatment for each TK expressing cell line: WT: 20/2
GK1: 38/2 GK2: 35/1 GK3: 13/3. A visual representation of ApopTag results is
presented in Figure 36.

Cells positive for apoptosis stained very dark in contrast

to background. W e expect to fully screen these cells with treatment of a range of
GCV concentrations, and since this method is easily adaptable for analysis with
flow cytometry, it has been considered for future experiments to help generate
quantitative data.
The characterization of cell death and GCV metabolism have revealed a
positive correlation with increased GCV and increased DNA fragmentation
associated with apoptosis. The next section describes our results testing the
HSV-tk variants in the in vivo TRAMP model.

In vivo TRAMP Model
HSV-TK Variants
HSV-tk active site variants have been tested recently in vivo, and they
proved to be effective at reducing tumor burden (51). However, this model was
based in SCID mice, therefore the role of the immune system could not be
evaluated. Fortuitously, when we moved to EVMS, we formed a collaboration
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with Dr. Ciavarra’s laboratory, which provided access to an excellent animal
model, the transgenic adenocarcinoma mouse prostate (TRAMP).

Greenberg et

al. developed the original TRAMP model in which the rat probasin promoter
drives the expression of SV40 large T-antigen that is restricted to the epithelial
cells of the prostate gland in C57BI/6 mice (167). A derivative of this model was
then developed using cell lines derived from the in vivo TRAMP tumors (TRAMPC1, C2, C3) (168), and since these cell lines no longer express T-antigen at the
RNA or protein level (168), and they can be used to evaluate immunotherapeutic
response to treatments. W e obtained a derivative of these cells lines, termed
TRAMP-C1P3, that had been serially passaged three times in mouse prostate
gland of C57/BI6 mice and clonally re-isolated developed by Drs. Kenneth
Somers and Richard Ciavarra at Eastern Virginia Medical School.
In order to begin our animal model, HSV-tk expressing TRAMP-C1P3 cells
were established by transfection with wild type HSV-TK, G K1, GK2, and GK3
plasmids as described in Materials and Methods. The IC50 for GCV for all
TRAMP.tk cell lines was determined and appeared comparable with a human
prostate cell line (DU145.TK) and the colon cell line HCT116.TK used in many of
our studies. Those concentrations are presented in Table 8.
A TRAMP-GK3 clone that robustly expressed GK3 was never successfully
isolated and characterized. It is important to note that all TK variants were tested
in combination with UCN-01, and MTT assays revealed that the TK variant did
not impact the enhanced killing effect of UCN-01 with GCV (data not shown).
This was important to verify since the overall goal of our laboratory is to combine
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the multiple approaches in the animal model to investigate efficacy. These
utants were subsequently tested in the TRAMP animal model with GCV only as
described in the next section.
C57/BL6 mice were injected with 5X106 cells comprised of 90% parent
TRAMP-C1P3 and either 10% TRAMP-TK (wt)(n=18), 10% TRAMP-GK1 (n=18),
10% TRAMP-GK2 (n=6). After 20 days, mice were randomized within their
respective groups and half were treated with GCV (7 or 70 mg/kg, i.p. once daily)
for 5 days, and beginning on day 22, tumor volumes were monitored by
measurement with calipers. On each graph in Figure 37, days 21-25 represent
the 5 days of prodrug treatment. The WT-TK and GK1 tumors were equally
responsive to the 70mg/kg doses. What is not evident with GK1 is that half of the
tumor volumes were less than 1000 mm3 at day 40, while other tumors grew out
in the same cohort. There was an apparently greater tum or reduction with
7mg/kg GCV in TRAMP-GK1 mice than with WT, consistent with GK1 being
more efficient at metabolizing GCV, at lease at low doses. Interestingly, TRAMP
GK2 (N7530) tumors responded the best to 70mg/kg GCV that was either equal
or superior to W T or GK1.
At approximately day 38-40 at treatment termination, tumor samples from
the responding mice were fixed in formalin for H&E staining. Figure 38 shows
images from the H&E stains, taken near the border between the more active
tumor cells near the surface versus the less dense core regions. Each section
was observed by a pathologist, Dr. Jose Diaz (Dept, of Anatomy and Pathology,
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EVMS), and arrows in the figure indicate evidence of apoptosis.

It was obvious

in looking at the entire group of tumor slices that relative to untreated tumor
samples, GCV treatment led to less dense tumor cores with evidence of pockets
of apoptotic cell death and large regions of necrotic cells. The tissues from WT
and GK1 tumors treated with GCV looked very similar in this regard. However,
there was a striking increase in interior hemorrhagic necrosis in GCV treated
GK2 tumors as evidenced by the presence of pools of red blood cells and
increased number of necrotic cell remnants mixed with apoptotic cells. Future
immune cell infiltration studies are suggested in Chapter VI: Conclusions.

In vivo assessment of GCV. UCN-01. and U+G
McMasters et al. discovered the enhanced cell killing with the combination
of GCV and UCN-01 (6 0 ), and Chapters III and IV were dedicated to determining
the underlying molecular mechanism of their action. This final section tests their
efficacy in vivo. As determined by MTT assay in TRAMP cells, the IC50for GCV
was found to be 0.1 pM, and for UCN-01, 0.03 |aM. The combination of GCV and
UCN-01 was additive in cell killing in TRAMP.TK cells in vitro. (Data not shown)
Twenty C57/BL6 mice were injected ectopically (into the chest wall) with
5X106 cells comprised of 90% parent TRAMP-C1P3 and 10% TRAMP-Tk cells.
Tumors were allowed to grow for 22 days, and then mice were randomized into 4
groups of 5 mice each. Group 1: 70mg/kg GCV once daily for five days (day 2226). Group 2 : 2mg/kg UCN-01 for 5 days. Group 3: Combination of 70mg/kg
GCV once daily for five days and 2mg/kg UCN-01 for 5 days. Group 4 : Control,
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Fig. 38. H&E Stains of GCV treated TRAMP tk, TRAMP GK1 and TRAMP
GK2 tumor slices. At approximately day 38-41 at treatment termination, tumor
samples from the responding mice were fixed in formalin for H&E staining.
Arrows are indicative of apoptosis
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Fig. 39. TRAMP ectopic tumor model evalution of GCV, UCN, and U+G.
Twenty C57/BL6 mice were injected ectopically (into the chest wall) with 5X106
cells comprised of 90% parent TRAMP-C1P3 and 10% TRAMP-TkK cells.
Tumors were allowed to grow for 22 days, and then mice were randomized into 4
groups of 5 mice each. Drug treatments: GCV: 70mg/kg GCV once daily for five
days (day 22-26). UCN-01: 2mg/kg UCN-01 for 5 days. U+G: the combination of
70mg/kg GCV once daily for five days and 2mg/kg UCN-01 for 5 days. Each point
is an average of at least 5 mice per condition.
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no treatment.

Tumor volumes were determined at day 22 and every 3-4 days

thereafter until termination. As shown in Figure 39, the doses tested were
effective at reducing the tumor burden, however, the combination with UCN-01
did not produce significantly enhanced tumor reduction compared to GCV alone.
In vitro studies with TRAMP-tk cells revealed that these cells have a
particularlyhigh bystander effect, which is not necessarily representative of true in
vivo effects, (data not shown) Animals were not observed at later time points
after treatments as they were all harvested by day 45.

Discussion
The generation of GCV-kinases has helped define the role of GCV
metabolism on cell cycle and cell death. The HSV-tk variants are very promising
for the manipulation of therapy based upon the different types of cell death they
may be signaling. Table 9 shows the cumulative descriptive data we have on the
variants thus far. Because we believe that the deliberate induction of a nonapoptotic cell death could make a significant contribution to over therapeutic
efficacy, it will be interesting to determine if the altered metabolism of N7530 or
N30-3 HSV-tk variant will translate into differences in the in vivo immune
response in animal tum or models. W e are looking forward to testing the variants
more extensively in vitro and in vivo with UCN-01. The successful completion of
several animal studies using the TRAMP model boosts our confidence in
subsequent studies that will be more in depth. A summary of future experiments
is suggested in Chapter VI: Conclusions.
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CHAPTER VI
CONCLUSIONS

The combination of UCN-01 and HSV-TK/GCV represents a new lead
strategy for improving current cancer gene therapy protocols, regardless of p53
status, via alternative and additional DNA damage pathways. It was important to
characterize these pathways such that existing treatments can be more fully
exploited and optimized, and this information could also be utilized for the
development of new chemotherapeutic drugs.

Three diverse philosophies of

methodology were used to benefit the best cancer therapeutic outcome using
HSV-tk gene therapy combined with the chemotherapeutic drug UCN-01: 1) Cell
cycle and death mechanism characterization 2) DNA damage signaling network
delineation and 3) Therapeutic modality evaluation in vitro and in vivo. All of
these approaches combined provided both a molecular basis guide for future
experiments and a foundation for more in depth in vivo studies. UCN-01 is a
very exciting and intriguing compound that tested our knowledge of signal
transduction (specifically DNA damage and cell death pathways), as most clinical
studies and in vitro studies have shown that it is an excellent therapeutic partner
with other modalities. The new pathways identified and the unique properties of
UCN-01 in our system could lead to novel directions of study and provide new
therapeutic targets and directions of study. The following pages include
conclusions of the results presented in Chapters lll-V and suggested future
directions:
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Chapter III: Conlusions and future directions
Conclusions:
1. GCV treated HSV-tk expressing cells undergo an S-phase arrest.
2. UCN-01 has variable effects on the cell cycle, possibly inducing a
decrease in S-phase cell population, although cells continue to cycle
through more quickly than control. UCN-01 causes mitotic proteins to
degrade as detected by western blot.
3. The combination of U+G allows the cells to progress through the cell cycle
initially; however undergo an S-phase specific cell death in the end.
Concommitently, key mitotic proteins are degraded but at a slower rate
than cells treated with UCN-01 only.
4. Order of addition of the two drugs resulted in UCN-01 dominating the
effects whenever it was added. Changing the order of addition of our
treatments has not yet affected tumor cell toxicity. This remains to be
tested more thoroughly in an animal model.
5. Distinct SELDI-TOF generated, low mass protein signatures for each drug
treatment were detected in whole cell and nuclear lysates. Identification of
these differentially expressed proteins could provide a new way to
evaluate molecular mechanisms and treatment efficacies of cancer
therapeutics.
6. Two dimensional gel electrophoresis is a powerful tool in discovering
components of the GCV/UCN-01 mechanism of cell death and will be the
subject of future in depth studies of this system.
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Future directions
We originally hypothesized that the targeted destruction of key mitotic
proteins by UCN-01 contributed significantly to its cytotoxicity with GCV.
Although gene array analyses were performed (data not shown), we never
observed levels of the transcripts of those mitotic genes to be significantly
reduced. Prior to initiating more protein studies, the effects of UCN-01 and U+G
treatments on the suppression of transcripts should be done using methods other
than gene arrays. Reverse transcriptase PCR (RT-PCR) is a powerful tool to
look for the transcripts after isolating mRNA from cells treated with the drugs and
harvested at multiple time points. Primers for Cdc25C, cyclin B, CDK1, and
others could be used to determine the levels of these transcript levels. However,
it is also possible that these events are occurring at the protein level, in which
case we have considered pulse chase radiolabeling of proteins coupled with
immunoprecipitation of the same mitotic proteins to see if indeed they are going
through drug dependent targeted degradation. This might also help us zero in on
the particular mode of cell death such as autophagy or mitotic catastrophe.
Another possibility is that the protein levels are purely indicative of cell
cycle phases. W e would address this by coupling propidium iodide or 7-AAD
staining for cell cycle analysis and using an antibody for the cell cycle protein of
interest. W e would not need to synchronize cells, and we would have valuable
data giving us the phase of the cell cycle and if the cell cycle protein was being
expressed. Also, the active mitotic indicator histone 2B could be used to help
define the G2/M boundary and identify cells undergoing mitosis. ApopTag™

R eproduced with permission of the copyright owner. Further reproduction prohibited without permission.

122
could be combined with any of these stains or antibodies to also quantitate
numbers of apoptotic cells.
With the acquisition of new imaging equipment, duel fluorescent stains, a
gel spot picker, and GE Amersham Decyder software, future experiments can be
planned for more thorough studies and identification of proteins of interest from
2D gels. Total protein measurements as well as phosphorylated and
glycosylated proteins methods of detection are also now available in our
laboratories. Cell lines and treatments are recommended in Table 10.
Furthermore, in depth 2-dimensional gel electrophoresis analysis of the
UCN-01 interactome would be carried out by coupling UCN-01 to an epoxysepharose column to isolate all UCN-01 interacting proteins. Spots identified by
PD Quest Software from BioRad would be used to select spots of interest to be
sequenced by the Eastern Virginia Medical School protein sequencing facility.

Chapter IV: Conlusions and future directions
Conclusions:
1. Treatment of cells with UCN-01 results in DNA double strand breaks
2. Cumulative data indicate that UCN-01 may be directly causing physical
damage to DNA systematic fashion, and base excision repair could be
involved in its repair. The combination of the base excision repair inhibitor
and methoxyamine and UCN-01 caused sub-additive potentiation of cell
killing.
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3. The cumulative effects of UCN-01 treatment are very complex involving
cell cycle checkpoints, survival pathway proteins, apoptotic proteins, DNA
damage signaling and repair proteins resulting in equilibrium shifts
between apoptosis, survival, cell cycle progression and arrest. The
underlying mechanism that allows UCN-01 to significantly improve the
therapeutic window of DNA damaging drugs and other chemotherapeutic
agents already available as treatment options may be due to its ability to
damage the DNA itself while launching a multi-tiered assault on the tumor
cells survival network.
The exact sequence of events leading to cell death after treatment of cells
with UCN-01 is largely unknown. W e have hypothesized in general that the
physical interaction of UCN-01 with DNA causes a cascade of DNA damage
signaling while also causing replication stress leading to stalled replication forks
during S-phase. Also, the incompletion of base excision repair that is believed to
be involved in the repair of UCN-01 induced lesions causes single strand breaks
in the DNA. The cell cycle data presented in Chapter III have indicated
interesting and non-classical responses to DNA damage after UCN-01 treatment,
but this could be due to the fact that UCN-01 can abrogate the arrest induced by
Chk1 in S and G2 phases of the cell cycle, and of several BER single strand
break intermediates converting into DSBs. Detection of the double strand break
marker yH2AX in S-phase could represent double strand breaks from stalled
replication forks while yH2AX detection in G1 or G2 could be due to immediate
damage or repair. Persistance of yH2AX is indicative of a lesion that remains
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unrepaired. High induction of H2AX phosphorylation has been detected in Sphase cells treated with UV irradiation (169). It would be interesting to correlate
the phase of the cell cycle with H2AX phosphorylation via flow cytometry after
UCN-01 treatment.
Figure 40 is a suggested depiction of the many effects (including DNA
binding) and interactions that UCN-01 has within DNA damage signaling
network. The interaction mapped out in blue includes how GCV incorporation
might fit into the over mechanism.

Future Directions
The interaction of UCN-01 with DNA could be tested a number of different
ways. Another indolocarbozole antibiotic (AT2433-B1) structurally related to
rebeccamycin and staurosporine was shown to bind strongly to DNA (170).
Carrasco et al. determined this interaction using DNase 1 footprinting
complimented with BiaCor Surface Plasmon Resonance measurements (170).
Another approach would be to use absorption spectroscopy combined with
equilibrium dialysis. Bible et al used this method to compare the binding of
flavopiridol DNA binding to known intercalators doxorubicin and pyrazoloacridine,
and they further investigated the binding properties with Nuclear Magnetic
Resonance Spectroscopy (171).

Equilibrium dialysis and enzymatic cleavage of

the DNA are both methods that are easily accessible, and collaborations could
be sought in the other areas (NMR and Surface Plasmon Resonance) if we
determine they are necessary.
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Chapter V: Conclusions and future directions
Conclusions
1. The best GCV specific kinase, GK1 (Q7530), had the highest GCV
incorporation into the DNA, the most rapid S-phase arrest, and one of the
best killing efficacies in vitro and in vivo. HSV-tk variants have different
GCV metabolic properties, and we believe these may be exploited for the
best tumor cell killing combination by possibly inducing several
complimentary modes of cell death.
2. The TRAMP model is useful for evaluating HSV-tk/GCV gene therapy and
revealed that the therapy can be successful at reducing tumor burden
3. HSV-tk variants delivered by an adenovirus combined with GCV, ACV,
and UCN-01 in an in vivo model is the most promising approach for our
lab to contribute to the growing need for improved HSV-tk gene therapy
schemes.

Future Directions
The core strategy for future aims in the therapeutic branch of our research
includes a larger scale animal model study where multiple facets of the therapy
will be tested and evaluated. This includes extensive proteomic analysis of
serum and tum or homogenate from mice within the study and other methods
listed in Table 11. Data gathered from the animal model will include animals
treated with titrated concentrations of both UCN-01 and GCV to determine the
lowest effective dose. Order of addition of the drugs will be tested to determine if
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either can sensitize the tumor to further treatments.

Those experiments will aid

us in the future planning of experiments that will include an immune component
such as the FLT-3 ligand or cytokines such as IL-2. The distant bystander effect
is one of the most promising angles for the further improvement of HSV-tk/GCV
gene therapy through multiple modalities. Vile eta l. in their 1997 review
summarized it best when they claimed:
In effect, if an immune response can be effectively activated
against tumor cells, the burden of gene delivery efficiency,
specificity and inadvertent toxicity should be transferred from the
gene therapist onto the immune system. (45)

The outcome of our preliminary animal data was very promising and an
outline of suggested future animal model studies is outlined in Table 10. Parallel
experiments in the TRAMP-TK expressing cell lines, as outlined in Table 11,
could also be done to further support these suggested in vivo studies.
The combination of results, conclusions, and future directions from
Chapters lll-V come together for suggesting an interesting and a full-scale
approach for characterization of multiple cell lines with diverse molecular
backgrounds after UCN-01 and other drug treatments. It would be especially of
interest to determine the mechanism of resistance or sensitivity to the drug
schemes tested in these diverse cell lines. In addition to investigating the
discrepancies between SW620s and HT29 sporadic cell lines to drug treatments,
a variety of DNA damage signaling repair knockout pairs could be further tested
such as HCT116 colon cancer cells which are already MMR deficient, HCT116
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Table 10 Suggested future animal studies in the TRAM P model

Animal Studies
TRAMP wild type and
HSV variants

Treatment schemes
Adenoviral tk delivery

Analysis Methods
Tumor measurements

Concentration titration and
drug order of addition:
GCV, ACV, and UCN-01

Immune cell infiltrate
Flow cytometry
Immunofluorescence
H&E staining
ApopTag™

Immunotherapy such as Fit3 ligand

SELDI and 2D Gels
Tumor homogenate
Mouse sera
Laser Capture
Microdissection

Cell Lines
SW620
HT29
DU145
MCF-7
NCM460
CSC-1
MDA-345

Table 11 Summary o f Future in vitro Experiments
T reatments
Analysis Methods
None
2D gels
Silver staining
GCV (if expressing
SYPRO Ruby
TK)
ProQ Diamond
Emerald Green
ACV
Differential In Gel
Electrophoresis (DIGE)
UCN-01
Flow Cytometry
NU7026
BrDU labeling; cell cycle; cell
cycle proteins; Apoptosis
(markers and SubGO
Methoxyamine

M095J/K
HCT116
p53 -/- and +/+
p21 -/- and +/+
Chk2 -/- and +/+
UCN-01 resistant
TK variants

Proteasome
Inhibitors
Caspase Inhibitors
Concentration
ranges,
combinations, and
order of addition of

TRAMP tk variants

Western blots and Confocal
Microscopy
Chk1; Chk2; BRCA;
ATM/ATR; H2AX; H2B;
53BP1; phospho cdc25C and
cdc25A; pRb
PFGE (neutral and alkaline)

all drugs tested
SELDI-TOF
MTT and
Clonal Survival assays
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p21-/+, HCT116 p53-/+, and HCT116 Chk2-/-, and M095K/J glioma cells
(proficent and deficient in DSB repair). Breast cancer cell lines (MDA-345 and
MCF-7) could be also be subjected to a panel of treatments and analyzed as
outlined in Table 11. The BER inhibitor methoxyamine and the DSB repair
inhibitor NU7026 would be used cooperatively in our in methods investigating the
DNA damage signallig pathways. Finally, a UCN-01 resistant FICT116 cell has
been developed in our laboratory, and in depth investigations using the proposed
analysis methods in Table 11 could also reveal the mechanism of damage by
UCN-01.
All of the cell lines suggested in Table 11 are already currently available
for these suggested studies and are part of our well -defined cell culture
repertoire. However, we have also considered using Chinese Hampster Ovary
(CHO) cells for assessment of DNA repair pathway components. There are
several DNA repair protein knockouts that are available and well described for
DNA damage repair studies.

Concluding remarks
Many treatment schemes for cancers have had profound and positive
consequences for the lives of patients; however, many therapies are limited
because of side effects on normal tissue and cells and drug resistance of tumors.
Elucidation of pathways could provide new targets for effective cancer therapies
and for design of rational strategies to target resistant cancers. Examples of the
recent progress made in molecular cancer therapeutics include Herceptin,
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Gleevec, and Iressa. These are powerful anti-cancer therapeutics for specific
cancers as reviewed in (172). Our molecular and therapeutic aims join to
contribute to these types of therapeutics and for answering the call for innovative
strategies that will benefit patients with cancers that are not responsive to current
treatments.
HSV-tk/GCV gene therapy is still providing hope for patients with
devastating cancers that do not have effective treatments. For example, in
November 2004 it was reported that adenoviral HSV-tk gene therapy with
intranvenous ganciclovir produced a clinically and statistically significant increase
in mean survival in malignant glioma patients (173). However improving gene
therapy delivery is currently the largest hurdle for gene therapy researchers to
overcome. W e have begun studies using adenoviruses in our own laboratory
and are looking forward to testing their efficacy in the animal model. Another
research angle being conducted by another graduate student in the Drake
laboratory ties in tum or specific expression of HSV-tk in colon cancer cells. It is
this project combined with the research stated within that will specifically and
aggressively evaluate gene therapy for colon cancers.
We are confident that with the data presented herein and our suggested
future studies that HSV-tk/GCV combined multiple approaches like UCN-01 will
make a significant contribution to the successful implementation of molecular
based therapies for cancers such as colon, breast, and prostate.
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